Author Index

A

Aanstoot H.J. 233
Abdel Khalek A.K.M. 222
Accili D. 1441
Adami H.O. 107
Ader M. 1254
Ahrén B. 260, 427, 936
Albert E.D. 671
Alberti K.G.M.M. 1314
Albon L. 688
Aldieri E. 831
Aldington S.J. 1107
Ally D. 238
Alm P. 978
Almgren P. 1138
Almind K. 1244
Alt A. 728
Altobelli E. 789
Alvarsson M. 15
Ambye L. 1244
Amiral J. 222
Anai M. 1439
Andersen T. 892, 1413
Anderson D.C. 1350
Anderton K. 944
Andreelli F. 358
Anfossi G. 831
Appleton I. 748
Armiento A. 1235
Armstrong E. 365
Artzner S. 1171
Arya S.C. 257
Asano T. 1439
Ashcroft F.M. 845, 903
Ashcroft S.J.H. 1240
Asscheman H. 214
Atkinson M.A. 13
Atsumi T. 579
Attardi G. 485
Auinger M. 1021
Aunola S. 793
Auwerx J. 892, 1033
Azam H. 534

B

Babu S. 380
Bacher T. 60
Bain S.C. 1017, 1030
Baldwin M.E. 419
Balkan B. 1324
Bangstad H.-J. 589
Baranyi É 497
Barazzoni R. 326
Barbetti F. 435
Bargero G. 297
Barnett A.H. 1017, 1030
Baron A.D. 493
Bashan N. 949
Basso M.D. 1120
Batstra M.R. 233
Baum H. 560
Baylis P.H. 534
Bazzigaluppi E. 1195
Beales P.E. 385
Beck-Nielsen H. 139, 899, 1046
Beck G.J. 90
Becker R. 1171
Bell G. 380
Bell G.I. 121
Bell J.D. 932
Bennett A. 944
Bennett P.H. 90, 1265, 1341
Berdanier C.D. 35
Bergkulla S. 1433
Berglund L. 1244
Bergman R.N. 238
Bergmann H. 1410
Bergmann R.N. 1254
Bergström A. 107
Bernal D. 1244
Beyer J. 465
Bhonde R.R. 257
Bhonsle U. 932
Bibby N.J. 292
Bierhaus A. 222
Biessels G.J. 693
Bilbao J.R. 119
Binz J.G. 545
Birkenbach M. 195
Bjerrum O.J. 472
Blaauwgeers H.G.T. 596
Blackshaw P.E. 365
Bloom S.R. 1048
Blouch K. 90
Bock T. 1212
Boehnke M. 238
Boel E. 472
Boffetta P. 297
Bolli G.B. 1151
Boms S. 1440
Bonfanti R. 1195
Böni-Schnetzler M. 160
Bonifacio E. 840, 1195
Bonmann E. 457
Boomsma F. 233
Borcea V. 222
Borra M. 68
Bosi E. 840, 1195
Bosia A. 831
Bottazzo G.F. 608
Boulton A.J.M. 748
Bouter L.M. 177, 926
Boutin P. 380
Boyages S.C. 1028
Brady L. 737
Brannath W. 1410
Bravi M.C. 1235
Bréant B. 711
Breban D. 302
Bretzel R.G. 603, 728
Brignetti D. 102
Bring J. 898
Brock B. 1302
Brouwer C.B. 382
Brown H.R. 545
Brownlee M. 603, 728
Bruining G.J. 233
Bruno G. 297
Buchanan K.D. 365
Buettger C. 1175
Burak W. 94
Buschard K. 195, 1212, 1302
Buteau J. 856
Buzzetti R. 119

C

Cameron N.E. 343, 1120
Carle F. 789
Carlsson S. 15
Carruba M.O. 495
Carvalho E. 819
Cassell P.G. 688
Cassone Faldetta M. 1235
Castaño L. 119
Cattabeni F. 693
Cavallo-Perin P. 297
Cavalot F. 831
Chaillous L. 330
Chakrabarti S. 1228
Chan J. 107
Chan L.C. 1250
Chang S.L. 250
Chaya S. 1404
Chèvre J.C. 480
Chen J.T. 250
Chen K. 28
Chen M.-C. 1199
Cherubini V. 789
Chi T.C. 250
Chiarelli F. 789
Chiba M. 995
Chitson P. 1050
Chiumello G. 1195
Chow W.H. 107
Chowdhury T.A. 1017, 1030
Chun T.-H. 702
Cisse A. 380
Claas F.H.J. 1379
Clark A. 1219
Clausen J.O. 896, 1011
Clausen J.T. 472, 728
Claypool M.D. 102
Cleland S.J. 1376
Cockburn B.N. 121
Coleman R.A. 639
Collins F.S. 238
Collins P. 944
Connell J.M.C. 1376
Cook J.R. 1293
Cooper M.E. 472
Cordain L. 383
Cordera R. 435
Cornaghi L. 118
Costamagna C. 831
Costanzo A. 1235
Cotter M.A. 343, 1120
Cox R.D. 120
Cseh K. 497
Cuesta-Muñoz A. 1175
Czernichow P. 711

D

Dabelea D. 1265
Dahlquist G. 589
Dalgaard L.T. 1413
Dallinger G. 302
Davalli A.M. 256
Davis E.A. 1175
De Clerck F. 81
de Courten M. 1050
De Giorgi G. 789
de Knijff P. 617
de Koning E.J.P. 1219
De Luca O. 1235
De Mattia G. 1235
De Ore K.A. 45
de Vegt F. 926
de Vries R.R.P. 443, 1379
de Wit E.C.M. 41
Dea M. 1254
Dean R. 35
Deinum J. 1006
Dekker J.M. 177, 617, 926
Dela F. 1282
DeLaney J.P. 1031
Deng D. 1228
Deninger M. 758
Derkx F.H.M. 1006
Di Luca M. 693
Di Marchi R.D. 1151
Dieplinger H. 1021
Dijk W van 351
Dina C. 480
DiPietro L. 113, 1269
Dobbins R.L. 128
Doi K. 702
Doni A. 351
Doria A. 94
Douglas Petersen L. 443
Downey D. 1228
Dräger A.M. 351
Draznin B. 310
Dresner A. 113, 1269
Dronsfield M.J. 1030
Ducluzeau P.-H. 358
Duinkerken G. 1379
Dullaart R.P.F. 897, 1345
Dunger D. 1030
Dunger D.B. 1017
Dupont S. 480
Durviaux S.M. 896, 1011
Dyer P.H. 1017, 1030

E

Easlick J. 688
Ebeling P. 1433
Ebina Y. 1441
Edna T.-H. 920
Edwards C.M.B. 1048
Efendic S. 15
Egan J.M. 45
Egusa G. 1168
Eiberg H. 896, 1011
Eisenbarth G. 380
Eizirik D.L. 1199
Ek J. 892, 896, 1011
Ekberg K. 812
Ekstrøm C.T. 1244
Ekström P. 978
Elam E. 28
Elbers J.M.H. 214
Elizalde J.I. 1350
Elliott H.L. 1376
Elliott R.B. 292
Emeis J.J. 351
Engelbach M. 465
Entes L.J. 102
Eriksson J. 238, 793
Esterbauer H. 302
Evans T. 1228

F

Fabris S. 419
Faehling M. 259
Fagerudd J.A. 519
Failla M. 987
Fairhurst F.E. 870
Falk Petersen K. 113, 1269
Falorni A. 789
Fathallah L. 1187
Federspil G. 495
Ferber K. 671
Ferguson M.W.J. 748
Fernández-Real J.-M. 1367
Fernqvist-Forbes E. 812
Fernström M. 826
Ferri C. 1235
Festa A. 1060, 1410
Flück C.E. 1067
Folefac V.A. 870
Foriers A. 188
Forouhi N.G. 932
Forrester J.V. 870
Forsblom C. 1138
Forsblom C.M. 1359
Forsén L. 920
Forst T. 465
Frederiksen S.K. 1244
Fredman P. 1212
Froguel P. 380, 480
Fuecker K. 635
Fujii S. 999
Fujikawa R. 1168
Fujikura K. 1204
Fujishiro Y.M. 1439
Fujita T. 151
Fujitani Y. 1093, 1417
Fukuda K. 763
Fukunaga Y. 702
Fukushima 1439
Fuller J.H. 68
Fumelli P. 539
Funaki M. 1439
Furukawa M. 450, 719
Fussgaenger R.D. 259

G

Galbo H. 1282
Gallina S. 480
Gallone G. 297
Gallus G. 840
Gamba P. 987
Gans R.O.B. 1345
Garancini M.P. 840
Garant M.J. 45
Gardoni F. 693
Garofano A. 711
Gaskill B.A. 545
Gautier J.-F. 28
Gearon C. 560
Gerber R.T. 81
Gerbitz K.-D. 627
Gesuita R. 789
Ghigo D. 831
Ghosh S. 238
Giani G. 1055, 1268
Giannattasio C. 987
Giltay E.J. 214
Giroix M.-H. 965
Gispen W.H. 693
Gleeson A. 944
Goalstone M.L. 310
Goitum K. 465
Goldstein M.K. 336
Gooren L.J.G. 214
Gopalakrishnan V. 1383
Gouin E. 330
Graier W.F. 167
Granger D.N. 1350
Grappiolo A. 987
Grauer P. 1171
Gravholt C.H. 1314
Greene D.A. 1187
Gregersen S. 1302
Greig N.H. 45
Gresh L. 380
Gribble F.M. 845, 903
Gridley G. 107
Grill V. 15
Grobbee D.E. 617
Grönhagen-Riska C. 519
Groop L. 1131
Groop L.C. 1138, 1359
Groop P.-H. 519
Grzeszczak W. 94, 632

H

Haffner S.M. 1060
Hägg E. 555
Haist K. 758
Hales C.N. 1060
Hall J. 1029
Hallmans G. 555
Hamada Y. 1404
Hamaguchi T. 621
Hämäläinen H. 793
Hamilton-Wessler M. 1254
Hammes H.-P. 603, 728
Hampe C. 555
Hanafusa T. 574, 621, 763, 1332
Hanaire-Broutin H. 1378
Haneda M. 151
Hanefeld M. 635
Hanifi-Moghaddam P. 1080
Hansen T. 896, 1011, 1244, 1413
Hara M. 380
Häring H.-U. 758, 1171
Harris D.P. 292
Harris N.D. 737
't Hart L.M. 617
Hashim Y. 120, 1240
Hata J. 566
Hauer B. 1171
Hauri C. 160
Hauser E.R. 238
Hawa M. 146, 1080
Hayashi H. 1441
Heine R.J. 177, 617, 926
Hell E. 302
Henkel E. 635
Henkels M. 222
Henningsson R. 978
Hermans M.P. 678
Hermansen K. 1302
Herrmann T.S. 639
Herzig P. 1055
Hidaka H. 151
Higashiyama S. 621
Hill J.P. 292
Hinokio Y. 995
Hinsbergh VWM van 351
Hirai A. 995
Hirai M. 995
Hiriart M. 1086
Hitman G.A. 688
Hjeltnes N. 826
Hodge A.M. 1050
Hoffmann G.F. 865
Hofman P. 596
Hofmann M.A. 222
Hohman TC 1120
Holemans K. 81
Holloway H.W. 45
Holman R. 608
Holmes-Walker D.J. 1028
Holness M.J. 802
Holst J.J. 1314, 1324
Holzäpfel A. 1410
Hoogenberg K. 1345
Hoorens A. 55
Hop W.C.J. 1006
Hopfner R.L. 1483
Höppener J.W.M. 427
Hopper J.L. 125
Hori M. 1093, 1417
Horikawa Y. 621
Horiuchi S. 878
Horn T. 1212
Horowitz M. 365
Horton V. 120, 608
Hosoda K. 702
Hotta N. 1404
Hou X. 188
Hummel M. 671

I

Iafusco D. 789
Ianari A. 146
Iannilli A. 789
Ibrahim S. 737
Ichikawa F. 98
Idehara C. 566
Igura T. 763
Ii S. 566
Ilanne-Parikka P. 793
Imagawa A. 574, 621, 1332
Imanishi M. 999
Inagaki N. 1204
Ingerslev J. 60
Inoue G. 702
Inoue H. 887
Inoue M. 702
Inoue S. 763
Inui Y. 763
Inukai K. 1439
Irsigler K. 1021
Isermann B. 222
Ishida M. 579
Ishikawa S. 579
Ishiyama-Shigemoto S. 98
Isotani H. 1266
Issad T. 527
Itakura M. 566
Ito M. 1404
Itoh H. 702
Itoh N. 574, 1332
Ivarsson S.-A. 181, 896, 1131, 1375
Ivy J.L. 310
Iwahashi H. 574, 621, 1332
Iwamoto Y. 1264

J

Jack A.M. 1120
Jacob S. 1171
Jakubowski J. 737
Jani D. 45
Janka H.-U. 671
Janmohamed S. 688
Jansson G. 555
Janus E.D. 1250
Jehle P.M. 259
Jenkinson G. 932
Jerums G. 472
Johansson B.-L. 958
Johnson A. 944
Jones S.C. 1113
Jönsson B. 1293

Jorgensen P.N. 1254
Josefsen K. 195
Joswig M. 222
Jude E.B. 748
Jun H.-S. 413

K

Kaas A. 1212
Kajimoto Y. 1093, 1417
Kallmann B.A. 1080
Kameoka K. 1266
Kaneto H. 1093, 1417
Kanitz M. 222
Kanninen T. 1138, 1359
Kanzaki M. 719
Karlsson S. 260
Karvonen M. 655, 1395
Kashiwagi A. 151
Kastendiek C. 671
Kasuya Y. 1404
Katagiri H. 1439
Kato K. 1404
Katsumori K. 1264
Kawamori R. 1417
Kawamura T. 1168
Kawano Y. 1071
Kawata S. 574, 763
Keegan A. 343
Keinänen-Kiukaanniemi S. 793
Keller E. 671
Keymeulen B. 1379
Khalfallah Y. 358
Khamaisi M. 949
Khandwala A. 102
Kido Y. 1441
Kikkawa R. 151
Kikuchi M. 1439
Kim A. 413
Kimura G. 999
King P. 365
Kishimoto M. 1417
Kitaoka H. 1266
Klein H.H. 245
Knott R.M. 870
Knowler W.C. 90, 1265
Koch M. 758
Koehler C. 635
Kofod H. 1302
Koh N. 1404
Kohner E.M. 1107
Kohtamäki K. 655
Koike T. 579
Koistinen H.A. 1433
Koivisto A. 1433
Koivisto V.A. 1151
Kojima H. 151
Kojima I. 450, 719
Kok A. 351
Kolb-Bachofen V. 457
Kolb H. 381, 1080
Kolterman O. 1029
Komori T. 1404
Kong M.-F. 365
Konishi Y. 999
Kopelman P. 688
Kostense P.J. 177
Kostner G.M. 167
Kotake K. 1204
Krempler F. 302
Kristensen K. 1302
Kronenberg F. 1021
Krook A. 826
Krssak M. 113, 1269
Kudara T. 763
Kuhlmann B.V. 1067
Kunt T. 465
Kuroki H. 1264
Kurowski T. 310
Kusunoki M. 958
Kuwajima M. 574
Kwansnik L. 1324
Kyvik K.O. 139, 899

L

Laakso M. 793
Labuz B. 632
Lacka B. 632
Lalain S. 330
Lam K.S.L. 1250
Lambert J. 214
Lampasona V. 1195
Lampeter E.F. 1080
Lancaster M.E. 545
Landin-Olsson M. 181
Lang H.J. 1187
Langefeld C.D. 238
Larrieta M.E. 1086
Larsen J.J.S. 1282
Larsen Z.M. 119
Larsson H. 936
Lathrop M. 120
Lau J. 472
Lauhkonen M. 793
Laurenti O. 1235
Lauro D. 1441
Laville M. 358
Lebel L. 1240
Lefrandt J.D. 1345
Lehto M. 1131
Lehto P. 793
Lehtonen A. 793
Lehtovirta M. 1359
Leitner J.W. 310
Lemaigre F.P. 896, 1011
Lenhard J.M. 545
Lenzen S. 849
Lernmark Å 181, 381, 555, 896, 1375, 1379
Leslie R.D.G. 13, 146, 1080
Levy J.C. 24, 678
Li L. 958
Li X. 1324
Lightfoot R.M. 545
Lin J. 603
Lin J.G. 250
Lindberg B. 181, 896, 1375
Lindblad P. 107
Linderkamp O. 865
Lindgren C. 1131
Lindner T.H. 121
Lindström J. 793
Ling Z. 188
Lips C.J.M. 427
Lipsanen-Nyman M. 1131
Lithell H. 1244
Liu I.M. 250
Löblein K. 1171
Lortz S. 849
Louheranta A. 793
Louwen F. 671
Lovejoy J.C. 1031
Lundquist I. 978
Luo J. 102

M

Ma O.C.K. 1250
Maassen J.A. 485, 617
MacArthur D.L.A. 1219
Macdonald I.A. 365
Mackay I. 608
Macor C. 495
Madsbad S. 1282
Maechler P. 485
Maegawa H. 151
Maerker E. 758
Maggi D. 435
Magnuson M.A. 1175
Magnuson V.L. 238
Maheux P. 634
Majchrzak A. 117
Mäkimattila S. 406
Makino H. 878
Makita Z. 579
Malaisse W.J. 286, 498
Malcangio M. 1308
Man in 't Veld A.J. 233
Mancia G. 987
Mangili R. 118
Manley S. 608
Mann N. 383
Mannelin M. 793
Markussen J. 1254
Martikkala V. 793
Masatsugu K. 702
Massucco P. 831
Mathews C.E. 35
Mathiesen E. 1006
Matschinsky F.M. 1175
Matsuda K. 887
Matsuhisa M. 1093, 1417
Matsuoka T. 1093, 1417
Matsutani A. 887
Matsuzawa Y. 574, 621, 763, 1332
Matthews D.R. 1107
Mattiello L. 831
Mauricio D. 896
Mazzanti L. 539
McCarthy M.I. 688
McGarry J.D. 128
McGraw R.A. 35
McKeigue P.M. 932
McKenna K. 534
McLaughlin J.K. 107
McNeil M. 1031
McShane P. 635
Medici F. 146
Mehta Z. 120
Meiracker AH van den 233
Melki V. 1378
Meregalli G. 118
Merletti F. 297
Meszaros K. 102
Metha Z. 1240
Meurrens K. 81
Meyer H.E. 920
Meyer T.W. 1341
Midthjell K. 920
Mielck A. 1268
Mierisova S. 932
Mijovic C.H. 1017
Miller J. 383
Miller M. 1308
Milner M.R. 28
Mire-Sluis T. 381
Miserendino R. 1324
Mitch W.E. 90
Miyagawa J. 574, 621, 1332
Miyazaki J. 621
Miyoshi H. 579
Moates M. 1175
Moczulski D.K. 94
Mogensen C.E. 60, 263
Møller A.M. 896, 1011
Moller D.E. 310
Møller Jensen D. 899
Moore D. 1254
Morcos M. 222
Moretti N. 539
Morgenthater N.G. 1440
Morino K. 151
Moritani M. 566
Moriwaki M. 574, 1332
Morris A.D. 534
Morris J.F. 1219
Morris R.J. 678
Morrissette D.L. 336
Mortensen S.B. 472
Movassat J. 1098
Muckersie E. 870
Mukherjee K. 1228
Müller R. 245
Mullick S. 932
Mullis P.E. 1067
Munday R. 849
Mutus B. 539
Myers B.D. 90
Mykkänen L. 1060

N

Nagano Y. 1266
Nagata S. 1332
Nair S. 812
Nakajima H. 574, 621, 1332
Nakamura J. 1404
Nakano M. 743
Nakao K. 702

Nakashima E. 1404
Nakayama M. 1404
Namba M. 574, 621, 1332
Naruse K. 1404
Naserke H.E. 1377
Nauck M. 1049
Nauck M.A. 373
Nawroth P.P. 222
Neele D.M. 41
Neil H.A.W. 24
Nelson R.G. 90, 1341
Neu A. 1055
Neverova M. 688
Newton R.W. 534
Nie L. 450
Nielsen M. 1171
Nielsen S. 60
Nieuwenhuis M.G. 427
Nijpels G. 177, 617, 926
Nikkilä K. 406
Nilsson M. 555
Nishimura H. 702
Nishio Y. 151
Nisoli E. 495
Nissén M. 1433
Nisticò L. 119
Niwa T. 728
Nolte L.A. 1071
Nomiyama J. 887
Nonaka K. 98
Noonan K. 688
Norman A. 15
Notkins A.L. 13
Nyholm B. 1314
Nylund S.J. 238
Nyrén O. 107

O

Obara S. 579
Obata T. 151
Oberkofler H. 302
Obrosova I.G. 1187
Odawara M. 631
Ogihara T. 1439
Ohsawa N. 1266
Ohta Y. 887
Oka T. 1439
Oka Y. 887, 1439
Okada N. 999
Okita K. 621
Okubo M. 1168
Okumura M. 999
Okuya S. 887
Onishi Y. 1439
Onkamo P. 1395
Ono H. 1439
Oosterwijk C. 427
Orho-Melander M. 1138
Oshida Y. 958
Ostendorf B. 1440
Östensson C.-G. 15
Østerby R. 589
Oue T. 621
Owens D. 944
Ozeki M. 719

P

Pacaud D. 413
Pagano G. 297
Paleari F. 987
Palmer J.P. 1265
Pan S.J. 310
Panarotto D. 634
Panés J. 1350
Parab P.B. 257
Park G.D. 1151
Parving H.-H. 76
Patsch W. 302
Paulik M.A. 545
Peakman M. 560
Pecqueur C. 688
Pedersen O. 245, 892, 896, 1011, 1244, 1413
Pedersen T.R. 1293
Pérez de Nanclares G. 119
Perin PC 68
Perkins A.C. 365
Persson B. 589
Persson G. 15
Petersen H. 472
Petrie J.R. 1376
Pettersson-Fernholm K.J. 519
Pettitt D.J. 1265
Pfützner A. 465
Pieper G.M. 204
Pinkett J.G. 102
Pipeleers D. 55, 188, 1379
Piperno A. 987
Piqué J.M. 1350
Pitkäniemi J. 655
Pociot F. 119
Poggiali F. 840
Poland D.C.W. 351
Pollock C.A. 1113
Popp-Snijders C. 177
Portha B. 965, 1098
Posthuma G. 427
Poston L. 81
Potashnik R. 949
Poulsen P. 139, 899
Pozza G. 118
Pozzilli P. 385
Pramming S. 1151
Pratley R.E. 28
Prentki M. 856
Princen H.M.G. 41, 897
Prisco F. 789
Proietto J. 419
Purdie D.M. 24
Pyke D.A. 146

Q

Qi W. 1113
Quartier E. 188
Qureshi A. 688

R

Rabini R.A. 539
Radatz M. 737
Rajbhandari S. 737
Ramachandran A. 688
Raoul M. 1175
Raskin D.B. 336
Rastas M. 793
Rathmann W. 1268
Ravussin E. 28
Reaven G.M. 102, 384
Reed M.J. 102
Rehling M. 60
Reneland R. 1244
Renn W. 758, 1171
Rett K. 758, 1171
Riaz S. 1308
Ricart W. 1367
Ricquier D. 688
Riemens S.C. 897
Rincon J. 1071
Riou J.-P. 358
Ritz E. 222
Rjasanowski I. 661
Robertson M. 870
Roden M. 113, 1269
Roduit R. 856
Roep B. 1379
Roep B.O. 443, 636, 1212
Rolandsson O. 555
Rondinone C.M. 819
Rønn B. 1006
Rönnemaa T. 1433
Rosella G. 419
Rosenbauer J. 1055
Rosenbloom C.L. 1350
Rothman D.L. 113, 1269
Rousseau G.G. 896, 1011
Rowland D.L. 336
Rudberg S. 589
Ruderman N. 310
Rudich A. 949
Ruef P. 865
Ruhé H.G. 926
Ruige J.B. 177, 617
Ruts L. 693
Ruyter I. 1031
Ryder J.W. 1071

S

Sada M. 574
Saito T. 702
Sakamoto K. 1093, 1417
Saker P.J. 688
Sakoda H. 1439
Salas A. 1350
Salmela P. 1433
Saloranta C. 1359
Saltevo J. 1433
Sánchez-Margalet V. 317
Sánchez-Soto M.C. 1086
Sastra S. 472
Sato A. 76
Sato T. 999
Sato Y 958
Satoh T. 621
Saucha W. 632
Saulnier C. 965
Saunders H.J. 1113
Sawada N. 702
Saï P. 330
Schaeffer G. 167
Schalekamp MA.D.H. 1006
Schalkwijk C.G. 351
Schaper F. 635
Schauf B. 465
Schenker M. 671, 1377
Scherbaum W.A. 1440
Schernthaner G. 1410
Schiekofer S. 222
Schleicher E. 603
Schleicher E.D. 728
Schlingemann R.O. 596
Schloot N.C. 1212
Schlosser M. 661
Schmetterer L. 387
Schmitz A. 60
Schmitz O. 1314
Schneider S. 465
Schott M. 1440
Schuit F. 188, 1199
Seino S. 1204
Seino Y. 480
Seissler J. 1440
Selmi F. 737
Shattock M. 608
Shaw J.E. 1050
Shaw J.T.E. 24
Shearing P.A. 1314
Shibata H. 450, 719
Shibata T. 151
Shikata K. 878
Shintani M. 702
Shnawa N. 1410
Shulman G.I. 113, 1269
Silberbusch J. 382
Sima A.A.F. 773
Siquier K. 527
Smit A.J. 1345
Smith S.R. 1031
Smith U.P. 819
Smulders Y.M. 382
Snehalatha C. 688
Sobieska M. 117
Soler A. 1071
Song S. 419
Sørensen L.R. 195
Sørensen T.I.A. 892, 1413
Sorger M. 671
Soulis T. 472
Southam L. 120
Stacher-Janotta G. 1410
Stacher G. 1410
Stahl R.A.K. 1425
Stehouwer C.D.A. 177, 214, 351, 926
Steinberg H.O. 493
Stephure D. 413
Stevens E. 560
Stevens L.K. 68
Stobbe I. 1379

Stolk R.P. 617
Stratton I. 608
Stratton I.M. 1107
Strebelow M. 661
Strobel A. 527
Strosberg A.D. 527
Stumvoll M. 1171
Sturis J. 1314
Sugden M.C. 802
Sugimoto H. 878
Sugimoto K. 773
Sugo M. 743
Sullivan Jr E.P. 555
Sundkvist G. 181
Sundseth S.S. 545
Sundvall J. 793
Suschek C.V. 457
Susini S. 856
Suzuki M. 1204
Suzuki S. 995
Svanberg L. 181
Svanström L. 15
Sweet I. 1175
Szydlowska I. 632

T

Taghavi J. 120
Takata K. 1204
Tamura S. 574, 763
Tan M. 90
Tanabe K. 887
Tanaka S. 999
Tanaka T. 702
Tanizawa Y. 887
Tannous M. 539
Tarnow L. 76
Tattersall R.B. 365
Tauber J.P. 1378
Temelkova-Kurktschiev T. 635
Teppo A.-M. 1433
Tessari P. 326
Thallas V. 472
Thijssen J.H.H. 427
Thomas E.L. 932
Thompson C.J. 534
Thomsen J.L. 1302
Thorburn A.W. 419
Tiedge M. 849
Tiengo A. 326
Tirosh A. 949
Toivanen L. 655
Tomkin G.H. 944
Tomlinson D.R. 1271, 1308
Tomonari S. 566
Tonello C. 495
Toyota T. 995
Trenkwalder E. 1021
Treusch A. 222
Tritschler H. 222
Trovati M. 831
Trussell R.A. 413
Tsuchida K. 579
Tsuji T. 574
Tsukuda K. 1439
Tuomi T. 1131
Tuomilehto-Wolf E. 655
Tuomilehto J. 238, 655, 789, 1395
Turner R. 120, 608, 1240
Turner R.C. 24, 678, 1107
Turpeinen A. 793

U

Ueda S. 1376
Ugi S. 151
Urhammer S.A. 892, 896, 1011
Urhammmer S. 1244
Utermann G. 1021
Utriainen T. 494
Uusitupa M. 793
Uwakwe N. 688

V

Vaag A. 139
Vaag A.A. 899
Väänänen S. 1395
Valle T. 238, 793
Vallier P. 358
Van Assche F.A. 81
van den Ouweland J.M.W. 485
van der Does F.E.E. 617
van der Keur M. 443
Van Obberghen E. 1244
van Rood J.J. 1379
van Roon A.M. 1345
Van Schravendijk C. 188
Varadi A. 1240
Vega N. 358
Veglio M. 68
Venerando A. 1195
Verbeek J.S. 1219
Vergani D. 560
Vestergaard H. 245
Vettor R. 495
Vidal H. 358
Vidaltamayo R. 1086
Vignini A. 539
Viikari J. 1433
Viljanen T. 793
Vinten J. 1046
Vionnet N. 480
Virtala E. 655
Vogel S.M. 113, 1269
Volk A. 758
von Kries R. 1055
Vrensen GF.J.M. 596
Vroom ThM 427

W

Wada J. 878
Wada R. 743
Waguri M. 574
Wahl H.-G. 1171
Wahl P. 222
Wahren J. 812, 958
Waldhäusl W. 1
Walker M. 1314
Wall K. 310
Wallberg-Heriksson H. 1071
Walter M. 671
Wang Y. 45
Ward J.D. 737
Warden C. 688
Warram J.H. 94
Wasada T. 1264
Wascher T.C. 167
Wasmuth H.E. 292
Wat N.M.S. 1250
Watada H. 1417
Watanabe H. 1168
Watanabe R.M. 238
Weiel J.E. 545
Weir G.C. 256
Weiss T. 222
Weitgasser R. 256
Weng J. 1131
Wenzel U. 1425
Wernroth L. 898
Wesslau C. 819
White D. 944
White M.F. 1244
Widén E. 1131
Wierusz-Wysocka B. 117
Wiktorowicz K. 117
Wileman S.M. 870
Wilken M. 472
Winkel S. 233
Winkler G. 497
Wipemo C. 1131
Wirbell L. 1131
Wohlrab U. 1440
Wolf G. 1425
Wolk A. 107
Wollheim C.B. 485
Wolzt M. 387
Wong L. 413
Worm D. 1046

X

Xu X.-J. 560

Y

Yagihashi S. 743
Yamada K. 98
Yamada T. 566
Yamada Y. 480
Yamagata K. 574, 621, 1332
Yamagishi S. 579
Yamakido M. 1168
Yamamoto K. 574, 621, 1332
Yamanouchi K. 958
Yamaoka T. 566
Yamasaki T. 621
Yamasaki Y. 1093, 1417
Yamashita J. 702
Yamashita K. 631
Yamasoba T. 1439
Yang Q. 621
Yano M. 566
Yasuda H. 151
Yasumura K. 579
Yki-Järvinen H. 406, 494
Yoon J.-W. 413
Yoshimasa Y. 702
Yoshimoto K. 566
Yoshioka K. 999
Yoshiuchi I. 621
Young A. 1029
Yuan X. 98

Z

Zaccaro D.J. 1060
Zajac J.D. 419
Zanetti M. 326
Zapf J. 160
Zerbini G. 118
Zhang Y.-Q. 719
Zhang Y.O. 450
Zhou J. 45
Ziegler A.-G. 671, 1377
Ziegler B. 661
Ziegler M. 661
Ziegler R. 222
Zielinski B. 539
Zierath J.R. 826, 1071
Zilberfarb V. 527
Zilow E.P. 865
Zimmet P. 608
Zimmet P.Z. 499, 1050
Ziyadeh F.N. 1425
Zozuliñska D. 117
Zukowska-Szczechowska E. 94, 632
Zychma M. 94
Zychma M.J. 632

Subject Index

KEY: A = Abstract in Supplement 1; b = Book Review; c = Correspondence; r = Review or Debate; w = Workshop report

A

Abbreviations *January & July issues, advertisement pages at front*
Acarbose A222-A224
A-cell, islet – clonal – amino acids, effect of A127
– islet, function within A135
Acetyl choline – receptor – muscarinic – subtypes A199
Actin – insulin secretion, role in A36
Activin A – islet B-cell differentiation induction 719
Acupuncture – hypoglycaemic effect in diabetic rats 250
ADA criteria *[see* Diabetes – diagnostic criteria*]*
Addison's disease – hypoglycaemia – counterregulation A70
Adhesion molecule – circulating – type 1 diabetes A319, A279
– – insulin, effect of A172
– integrin – type 1 diabetes A101
– intercellular – 1 – polymorphism – type 1 diabetes A90
– – endothelial cell expression – reperfusion 1350
– – NOD mouse islet B-cell, expression by A94
– – type 1 diabetes A100
– receptor – islet A150
– selectin – type 1 diabetes A100, A101
– vascular-cell – 1 – secretion – insulin. effect of 1235
– – type 1 diabetes A100
Adipocyte, adipose tissue – differentiation – thiazolidinedione, effect of 527
– GLUT – expression A170
– human cell line – PAZ6 527
– insulin signalling – type 2 diabetes 819
– oxidative stress, effect of – insulin resistance 949
– PPARγ, role of A15
– rat – PPARγ expression 702
– thiazolidinedione, effect of – differentiation 527
Adipogenesis – PPARγ 1033r
Adipose tissue – brown – insulin signalling A67
– glucagon effect A198
– exercise, effect of in obese type 2 diabetes A52
– metabolism A203
– microdialysis A52, A198
– – glucose monitoring A211
– PPARγ-2 expression – non-esterified fatty acids and 495c
ADP – platelet, effect on – diabetes 167
Adrenoceptor – α_2 – islet – lipid, effect of A144
– β_2 – polymorphism – insulin resistance syndrome 98
– β_3 – agonist – *db/db* mouse, effect on A181
– – – UL-TG 307 – metabolic effects A191
– – polymorphism – diabetic nephropathy 632c
– – – gestational diabetes A79, A80
– – – obesity 238, A21
– – – type 2 diabetes 238
Africa, diabetes in 901b
AGE *[see* Glycation – advanced end-product*]*
Age, Ageing *[see also* Elderly*]*
– heart-rate variability in diabetes and A295
– insulin secretion, effect on A160
– islet B-cell, effect on – malnutrition in early life, following 711
– skeletal muscle, effect on – GLUT4 expression A169
– sulphonylurea pharmacokinetics, effect on A244
Albert Renold Fellowship 1999 *EASD News Section 10/99 46*
Albumin excretion rate – apolipoprotein A phenotype and – type 1 diabetes A286
– diabetes A270-A272
– – LMW heparin, effect of 60
– heritability – type 2 diabetes families 1359
Albuminuria – glomerular hypertension, role of 999
– type 2 diabetes without retinopathy, cause in A268
Alcohol – hypoglycaemia recovery, effect on A219
Aldose reductase – inhibitor – epalrestat – diabetic neuropathy, effect on A293
– – galactosaemic nephropathy, effect on A276
– – IDD676 – diabetic neuropathy in rat, effect on A293
– – macrovascular disease, effect on 1404
– – neuropathy, effect on – ACE inhibitor synergy A292
– – sorbinil – streptozotocin-diabetic rat nerve A43
– – tolrestat A276
– – – diabetic autonomic neuropathy A300
– – zopolrestat A276
– polymorphism – diabetic nephropathy and 94, 1030c
– – diabetic retinopathy and A120
– – microalbuminuria A267
Aldosterone *[see* Mineralocorticoid*]*
Alginate wound dressing A307
Alloxan – islet B-cell cytotoxicity – mechanism of A139
– – GLUT2, role of A159
Amino acid – brain uptake during hypoglycaemia 812
Aminoguanidine – complications of diabetes, effect on in diabetic rat A276
– diabetic neuropathy, effect on – mechanism 743
– glomerular basement membrane, effect on A275
– glomerular cytokine-NO pathway, effect on in diabetic rat 878
– vascular hypertrophy in diabetic rat, effect on 472
– vascular reactivity, effect on in diabetic rat 204, A324
Aminoimidazole carboxamide riboside (AICA-r)
– streptozotocin diabetes, effect on A328
– vascular reactivity, effect on A324, A328
Amputation – lower-limb *[see* Foot – diabetes*]*
Amylin A145-A146
– amyloid formation – mouse 427
– analogue – pramlintide – therapy A232
– diabetogenic effect – transgenic mouse 427, 1219
– hypertension and in insulin resistance syndrome 1029c
– islet B-cell – hyperglycaemia, effect of 188
– islet cell proliferation, stimulation of A152
– precursors – islet B-cell – hyperglycaemia, effect of 188
Amyloid A, serum – troglitazone, effect of in type 2 diabetes 1433
Anaemia – erythropoietin-deficient – early diabetic nephropathy A278
Angiogenesis – retina 870
Angiostatin – retinal photocoagulation, role in A11
Angiotensin – converting enzyme – inhibitor – cough A285
– – – extracellular matrix, effect on A9
– – – glucose transport, effect on A176
– – – renal hypertrophy, effect on 1425

– – – renoprotection 263r, A10, A274
– – – – mechanism 1425
– – – – renal histology 589
– – – retinal blood flow, effect on A317
– – – sulphonylurea interaction A68
– – polymorphism – albumin excretion rate and A327
– – – diabetic microangiopathy and A326
– – – diabetic nephropathy and A269
– II – fibroblast, effect on – type 1 diabetes A9
– – metabolic effects A189
– – receptor – glomerular endothelial cell, role in A34
– – – inhibitor – diabetic nephropathy, effect on A274, A275
– – – – lipids, effect on in diabetes A289
– – – – losartan A289
– – – – renoprotection A10
Animal models – blood glucose measurement 256c
Antibiotic therapy for diabetic foot A310
Antibody – advanced glycation end-products – type 2 diabetes, in A57
– beta-casein A100
– endomysial – type 1 diabetes families A94
– GAD A94-A97
– – diabetes, adult-onset A210
– – diabetes classification, role in 499r
– – diabetes – type 1 3r, A92, A93
– – – type 2 A81
– – – – HLA and age associations 608
– – – – Pima Indian children 1265c
– – general population, in – adult – predictive value for diabetes? 840
– – – glucose tolerance & BMI association 555
– – neonatal cord blood 181, 1375c, 1445c
– – prediction of Type 1 diabetes, in A84
– – prevalence in schoolchildren 661
– – standardisation 381c
– gastric – type 1 diabetes A97
– gliadin – islet-cell-antibody-positive children, in A84
– glomerular basement membrane – diabetic nephropathy A10
– IA-2 A94-A97
– – general population, in – adult – predictive value for diabetes? 840
– – – glucose tolerance association 555
– – prediction of Type 1 diabetes, in A84
– – prevalence in schoolchildren 661
– – standardisation 381c
– – type 1 diabetes 3r, A92, A93
– insulin auto – neonatal cord blood 1375c, 1445c, 181
– – prevalence – school age 661
– – type 1 diabetes 499r
– islet-cell – children of type 1 diabetic parents – HLA-DR and 671
– – diabetes – type 1 – rapid progression, predicting A62
– – – type 2 1377c
– – – – glycaemic control, effect on A81
– – – – HLA and age associations 608
– – gestational diabetes 1377c
– – neonatal cord blood 1375c, 1445c, 181
– – – hereditary effect? 896c
– – prediction of Type 1 diabetes, in A84
– – prevalence – school age 661
– – WHO/JDF standard 381c
– p53 tumour suppressor protein – type 1 diabetes A97
– thyroid – islet-cell antibody-+ve children, in A84
– – type 1 diabetes A94, A96
– transglutaminase – type 1 diabetes 1195, 1441c
Antigen – islet-cell 3r
Antioxidant – α-lipoic acid – adipocyte insulin resistance, effect on 949
– – γ-linolenic acid conjugate A173
– – NF-κB binding, effect on 222
– – therapy – diabetic foot A308
– – – γ-linolenic acid with A292, A293
– aminoimidazole carboxamide riboside A328
– corpus cavernosum, effect on in diabetic rat 343
– nitecapone – diabetic nephropathy, effect on in rat A275
– phensuccinal – dithizone diabetes in rabbit, effect on A233
– Tanacan – diabetic neuropathy, use in A293
– thioctic acid *[see* Antioxidant – α-lipoic acid*]*
Apolipoprotein – A – phenotype – albumin excretion rate and – diabetes A286
– B – 48 – chylomicron – streptozotocin-diabetic rat 944
– – dyslipidaemia – diabetes – type 1 A287
– – metabolism – insulin, effect of – type 2 diabetes A19
– CIII – polymorphism – dyslipidaemia and A121
– E – albumin excretion rate and – type 1 diabetes A286
– – polymorphism – complications of diabetes A121
– – – type 2 diabetes A146
Apoptosis – embryo – high glucose A247
– Fas-mediated – BB rat A104
– glucose-induced – endothelial cell 259c
– insulitis – type 1 diabetes 1332
– islet B-cell – interferon-γ, effect of 560
– – malnutrition in early life, effect of 711
– – nicotinamide, effect of 55, A157-A159
– mediator – Fas *[see* Fas*]*
Arachadonic acid – islet B-cell A135
Arginase – diabetic foot ulcer, activity in 748
– isoforms – islet A142
Arginine – insulin secretion, effect on A127
Artery – carotid – intima+media thickness in type 2 diabetes A318
– compliance 214, 987, A187
Ascorbic acid *[see* Vitamin – C*]*
Atherogenesis – *Chlamydia pneumoniae*? A318
– hyperinsulinaemia, effect of – possible mechanism 310
– inhibitor – serine-protease inhibitor – diabetic heart A281
– oxidative stress A327, A328
– PPARγ, role of 1033r
Autofluorescence – skin – advanced glycation end-products A58
Autoimmunity *[see also* Antibody*]*
– superantigen – type 1 diabetes and 413
– T-cell subsets and – type 1 diabetes, in 443
Averrhoea bilimbi leaf extract – hypoglycaemic effect A232

B

BABYDIAB study 671
Baropedography *[see also* Foot – diabetes*]* A305, A306
Baroreflex *[see* Neuropathy – diabetic – autonomic*]* 1345
B-cell, islet *[see also* Insulin – secreting cell, Insulin – secretion*]*
– amylin expression – hyperglycaemia, effect of 188
– apoptosis A7, A13, A157-A159
– Ca^{2+} A132-A134, A13
– – microdomains A36
– – organelle-free – regulation A66
– – oscillation A132, A133
– – – mitochondrial potential, effect on A140
– – oxidative stress, effect of A139
– cell-cell interaction *[see also* B-cell, islet – connexin*]* A138, A142
– clusters – recruitment in A133
– connexin channels – function, effect on A46
– cross-talk between glucose and fatty-acid signalling 128 r
– cytotoxicity A13
– – bovine *vs* human islets A31
– – cytokine-induced A155-A157
– – interleukin-1β-induced – gene expression 1199

B-cell, islet
– – lipid, role of 128r
– – nicotinamide, effect of 55
– – non-esterified fatty acids, effect of A143, A144
– – oxygen free radicals – nitric oxide synergy 849
– – poly(ADP-ribose) synthetase role A8
– differentiation *[see* B-cell, islet – regeneration*]*
– Dynabead immunopurified A157
– early growth-response gene (Egr-1) – glucose, induction by 195
– electrical activity A65
– function *[see* Insulin – secretion*]*
– GAD expression – insulin secretion activity and 1080
– glucose toxicity 1093
– GLUT2 expression – diazoxide, effect of A170
– growth *[see* B-cell, islet – regeneration*]*
– interferon-γ, effect of 560
– interleukin-1β, effect of – gene expression 1199
– ion flux A65, A66
– isolated 1199, 1302
– lipotoxicity 128r
– mass – malnutrition in early life, effect on 711
– maturation *[see* B-cell, islet – regeneration*]*
– metabolic signalling A126-A129
– mitochondria A139-A141
– Na^+ oscillation – tolbutamide-induced A133
– oxidative stress, effect of – p21 induction 1093
– proliferation *[see* B-cell, islet – regeneration*]*
– regeneration A13, A150-A152
– – GLP-1 as growth factor 856
– – leptin, effect of A56
– – MAPK role 450, A124
– – maturation – proteins expressed A155
– – nephrectomy, following A125
– – phosphatidyl-inositol 3'-kinase role 450
– – Smad proteins, role of 719
– – streptozotocin-diabetic GK Wistar rat, in 1098
– signal transduction A123-A125
Becaplermin – foot ulcer treatment A309
Beta-blocking agent – renoprotection in microalbuminuria – renal histology 589
Biguanide *[see* Metformin*]*
Bimoclomol – nerve regeneration, effect on A294
Blood – flow – choroidal 387r
– – laser Doppler method A306, A325
– – nerve – diabetic neuropathy, role in 773r
– – – protein kinase C, effect of 1120
– – ocular 387r
– – retinal 387r
– – – streptozotocin-diabetic rat 1228
– – skeletal muscle – insulin, effect of 493c, 494c, 1376c
– – skin – diabetes A306, A325
– pressure – *[see also* Neuropathy – diabetic – autonomic*]*
– – ambulatory monitoring 263r
– – – diabetes, in A188, A283, A294
– – – diabetic nephropathy, in A73
– – – diabetic pregnancy, in A248
– – control – diabetes and A220, A250
– – diabetes – type 2 A106
– – – endothelial function A326
– – diabetic nephropathy, in A263
– – salt-sensitive – diabetic nephropathy families A284
– – variability – microalbuminuric type 1 diabetes 1345
Body – composition – arterial compliance and 214
– – bio-impedance measurement 214
– – – insulin effect A196
– – insulin sensitivity and 932
– weight – insulin therapy, effect of in type 2 diabetes 406
Bone – density – diabetes – cytokines and A83
– – Charcot foot A28
– – glucose tolerance and A107
– – measurement – ultrasonometric A28
– diabetes and 920
– regrowth following partial foot amputation A28
Bradykinin – glucose transport, effect on in insulin-resistant muscle A176
– receptor – polymorphism – diabetic nephropathy A266
Brain – hypoglycaemia, acute effect of – fuel uptake & metabolism 812
– imaging in mitochondrial diabetes 1266c
– post-synaptic protein phosphorylation – streptozotocin-diabetic rat 693
Breast feeding *[see* Infant feeding; Cow's milk*]*
Bronchial carcinoma – small-cell – GAD and IA-2 antibodies A95

C

Calcium – channel blocking agent – apoptosis, protection against A159
– – renoprotection A275
– – nifedipine – vascular reactivity and A324
– insulin-secreting cell *[see also* B-cell, islet – Ca^{2+}*]* A132-A134
– receptor – islet A134
Calnexin – insulin proreceptor, molecular chaperone for 435
CaMKII *[see* Kinase – protein – Ca^{2+}/calmodulin dependent IIδ2*]*
Capacitance – islet – exocytosis, effect of A45
Capillary – morphology – diabetes A325
– permeability – diabetes A75
– – endothelial PAL-E expression and – retinopathy 596
– – low-molecular-weight heparin, effect of in NIDDM 60
– – retina – glucose, effect of – nitric oxide role A34
Capsaicin – neonatal sensory denervation by – glucose disposal, effect on 260c
Carbachol – islet B-cell, effect on A133
Carbon monoxide – islet B-cell interaction, role in A142
– pathway – islet 978
Carboxymethyl-lysine, N^{ε} – diabetic retinopathy, accumulation in 728
– glomerular mesangium 878
– intracellular – diabetic retinopathy risk 603
Carcinogenesis – PPARγ, role of 1033r
Cardiovascular – reflex function – microalbuminuric type 1 diabetes 1345
– – coronary artery calcification A59
– – diabetes – type 2 A106, A107
– – – diagnostic criteria, effect of 1268c
– – diabetes care, effect on A253
– – diabetic neuropathy prediction by A50
– – diabetic retinopathy A317
– – fibrinogen – genetic polymorphism and CHD 1250
– – glucose intolerance – ADA *vs* WHO criteria A108-A111
– – homocysteine *[see* Homocysteine*]*
– – hyperinsulinaemia? A182, A187
– – insulin resistance itself 1264c
– – latent autoimmune diabetes in adult, in A281
– – leptin? A280
– – microalbuminuria A317
– – proinsulin, plasma A5
– – sialic acid, serum – type 1 diabetes A265
– – socio-economic state A6
– – von Willebrand factor A72
Casein – variants – β-casomorphin-7 – opioid 292
Castelli Pedroli Prize 1999 – Prof E Standl *EASD News Section 10/99 45*
Catalase – vascular smooth muscle protection by A33
Cataract – diabetic rat – aldose reductase inhibitor, effect of A276
Catechol-o-methyl transferase – inhibitor – nitecapone A275
CB1093 *[see* Vitamin – D – analogue*]*
Chaperone protein – calnexin 435
– SUR 903r
Chernobyl A159
Childhood and adolescence – diabetes in – abdominal obesity A208
– – African Americans – MODY-3 380c

– – coeliac disease A 262, A 263
– – epidemiology *[see* Epidemiology – diabetes – type 1*]*
– – glycaemic control A 18, A 209, A 55
– – – sc insulin infusion A 63
– – hypoglycaemia A 69
– – neonatal A 212
– – nocturnal hypoglycaemia A 219
– – Pima – GAD antibodies 1265 c
– – psychological aspects A 39, A 259
– – quality of life A 81
– – social & ethnic effects A 38
– – thyroid autoimmunity A 262
– screening for type 1 diabetes risk 661
Cholecystokinin – insulin secretion, effect on A 147
Cholera toxin B chain – innate immune system, effect on A 103
Cholesteryl ester transfer – protein – polymorphism A 208
Chromogranin-A 317
Chronobiology – diabetes – melatonin A 299
– heart-rate variation – diabetic autonomic neuropathy A 300
– leptin 641 r
CIGMA (continuous insulin infusion with model assessment)
– insulin sensitivity measurement 678
Clamp – hyperglycaemic – insulin secretion study A 79
– – proinsulin:insulin ratio in IGT 177
– hyperinsulinaemic – gastric emptying study 365
– – glycogen synthase A 15
– – leptin studies in man 641 r
– – pregnant rat 802
Cocaine and amphetamine-regulated transcript peptide A 194
Coeliac disease – screening A 84, A 94, A 99, A 99
– type 1 diabetes 1195, 1441 c, A 262
Cognitive function – hypoglycaemia, during – lactate, effect of A 70
Collagen type IV – renal expression – OLETF rat 579
Complement C3 – serum – troglitazone, effect of in type 2 diabetes 1433
Compliance – arterial *[see* Artery – compliance*]*
– drug – oral hypoglycaemic agent A 3
Complications of diabetes – biochemical mechanisms 1271 r
– DNA oxidation and 995
– endothelin, role of 1383 r
– EURODIAB study A 50
– genetics A 120
– geographical clustering A 6
– macrovascular disease A 48, A 49
– – insulin resistance and A 187
– mitogen-activated protein kinase role 1271 r
– quality of life, effect on A 37
Corpus cavernosum – endothelium-dependent reactivity – diabetic rat 343
Cortisol *[see also* Glucocorticoid*]*
– binding globulin – insulin secretion and A 190
– hypothalamo-pituitary-adrenal axis A 190, A 191
Cough – ACE-inhibitor-induced A 285
Cow's milk – β-casein – variants – type 1 diabetes and 292
C-peptide – action A 200, A 201
– diabetic neuropathy and 773 r
– erythrocyte deformability, effect on 465
– glucose uptake, effect on – rat 958
– isoforms in rat 958
– Na^+/K^+ATPase, effect on A 154
– nerve, effect on A 291
Craniopharyngioma – surgically excised – hyperinsulinaemia & growth A 202
C-reactive protein – *[see also* Vascular – inflammation*]*
– diabetes – type 1 351
– – type 2 – troglitazone, effect of 1433
– insulin resistance and A 24, A 61
Creatine – feeding – glucose metabolism, effect on A 167
Creosote bush *(Larrea tridentata)* 102
CTLA4 (Cytotoxic T-lymphocyte-associated protein 4)
– polymorphism – type 1 diabetes A 74
Cytokine *[see also* Interleukin, Tumour necrosis factor*]*
– expression – glucose, effect of A 30
– insulin resistance and – innate immune system role 497 c
– islet B-cell cytotoxicity – nicotinamide, effect of 55
– islet B-cell, effect on A 13
– PPARγ suppressed – thiazolidinedione, effect of 702
– type 1 diabetes – twin study 1080

D

Dehydroepiandrosterone – 7-oxo – retinal pericyte protection A 316
– *db/db* mouse, effect on – troglitazone comparison A 181
– glucose transport, effect on – muscle *vs* fat A 177
Dermal graft – cultured – wound application A 308
Dextran clearance 263 r
DHEA *[see* Dehydroepiandrosterone*]*
Diabetes – Africa, in 901 b
– care – Asian patients in UK A 220
– – coronary revascularisation A 279
– – France A 238
– – multidisciplinary – video consultation system A 307
– – organisation A 249–254
– – psychological aspects *[see also* Education; Quality of life; Socio-economic state*]* A 255, A 257, A 37
– – – depression A 54
– – quality monitoring A 54, A 55, A 249–254
– – Staged Diabetes Management A 38, A 220, A 252
– classification 499 r
– – aetiological 499 r
– – African American children A 83
– – autoimmunity and HLA in type 2 diabetes 608
– – clinical staging 499 r
– – islet-cell antibodies 1377 c
– Control & Complications Trial 1 r
– – glycaemic control, effect on A 210
– diagnostic criteria 1 r, 499 r
– – ADA *vs* WHO A 43, A 44, A 108-A 111
– – cardiovascular risk factors and 1268 c
– – fasting plasma glucose 635 c
– – gestational diabetes A 261
– – obesity and 647
– – prevalence, effect on 1165
– fibro-calculous pancreatic A 191
– gestational A 259-A 261, A 79-A 81
– – HLA A 88
– – insulin resistance following A 161
– – islet-cell antibodies 1377 c, A 88, A 89
– International Textbook 901 b
– latent autoimmune in adult 499 r, A 209, A 210
– – cardiovascular risk factors A 281
– – prediction 840
– mitochondrial *[see also* Maternally-inherited diabetes, Gene – mitochondrial*]*
– – brain imaging 1266 c
– Prevention Study – obesity with IGT, in 793
– protein-deficient A 191
– research – epidemiology and 499 r
– type 1 – aetiology – auto-antigens 3 r
– – – environmental factors – animal contact A 88
– – – – β-casein A 1 A 62
– – – – infant feeding 292, A 75, A 88
– – – – social mixing 789, A 74, A 87, A 88
– – – – viruses A 83, A 99
– – – maternal age at delivery A 89
– – clinical course A 209
– – disease-modifying therapy A 92, A 93
– – – insulin – oral A 62
– – – – IV, with nicotinamide A 82
– – – interferon-α? 385 c
– – – nicotinamide 55
– – – – IV insulin and A 82
– – epidemiology *[see* Epidemiology – diabetes – type 1*]*
– – familial risk – EURODIAB ACE study – *Erratum* 261
– – incidence *[see* Epidemiology – diabetes – type 1*]*
– – islet immunohistochemistry at biopsy 574
– – non-autoimmune fulminant A 89
– – pathogenesis – initiation *in utero* 181, 1375 c, 1445 c

Diabetes
– – – – hereditary effect? 896c
– – progression – islet immunohistochemistry and 574
– – risk 661
– – – vitamin D in infancy, effect of 51
– type 2 – aetiology *[see also* Epidemiology – diabetes – type 2, Family study, Genetics, Insulin – resistance, Insulin – secretion, MODY*]*
– – – physical inactivity A113
– – animal model – streptozotocin-nicotinamide-diabetic rat A141
– – autoimmunity 555
– – carcinoma of pancreas screening A82
– – early adult onset A105
– – epidemiology *[see* Epidemiology – diabetes – type 2*]*
– – familial recurrence A105
– – gestational diabetes, following A81
– – heritability – twin studies 125r, 139, 146
– – MODY *[see* MODY*]*
– – prevention 499r
– – – lifestyle intervention programme – Finland 793, A47
– – prospective study – UK *[see* UKPDS*]*
– – risk factor – past gestational diabetes A81
– – youth onset *[see* MODY*]*
Diadenosine polyphosphates – insulin secretion, role in A138
Diaminophenazine – advanced glycation end-product inhibitor 472
Diazoxide – islet, effect on A126, A134, A137
– islet B-cell, effect on – cytotoprotection A8
– – GLUT2 expression A170
Dicarboxylic acids – insulin secretion, effect on A161
DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy & deafness) – genetics 627
Diet A213-A215
– diabetes – type 1 – extra treats – lispro insulin A239
– fat – high – insulin-resistant transgenic rat, effect on 419
– – insulin response to in polycystic ovary syndrome A162
– – low – insulin resistance, effect on A46
– – monounsaturated – vascular reactivity, effect on – type 2 diabetes A326
– – saturated – islet, effect on A144
– – – pregnancy, effect in – rat A174
– – – postprandial lipoproteins, effect on – diabetes A289
– glycaemic index A214, A215
– obesity with IGT, in – intervention study 793
– protein – glucose metabolism, effect on A163
Dipeptidylpeptidase IV inhibitor A41, A42
– *fa/fa* rat, insulinotropic effect in 1324
– NVP-DPP738 1324
DNA – oxidation – diabetes and smoking, effect of – complications and 995
Dog – galactose-fed beagle – coronary artery disease 1404
DOPA – insulin secretion, effect on A147
Dopamine – albumin excretion rate response – microalbuminuria prediction A271
– receptor – diabetic gastroparesis A301
Drug interaction – pioglitazone A228
Dyslipidaemia *[see also* Cholesterol; Hypercholesterolaemia; Hypertriglyceridaemia; Insulin – resistance – syndrome; Lipoprotein*]*
– apolipoprotein-B-dependent – diabetes – type 1 A287
– diabetes A285-A287
– genetics – apo-CIII A121
– prevalence – diabetes – type 2 A19
– smoking, effect of – type 2 diabetes A287
– type 2 diabetes families, risk in 24

E

Early growth response gene – Egr-1 – insulin-secreting cell 195
EASD – 35th Annual Meeting – Abstracts A1-A330
– AIDSPIT Study Group *EASD News Section 1/99c 13*
– Bayer Travel Fellowship *EASD News Section 15, 23, 27, 37*
– Eli Lilly Research Fellowship *EASD News Section 10/99 30, 47*
– General Assembly (Suppl 1) I
– history 1381r
– Paul Langerhans Research Fellowship 1999 *EASD News Section 10/99 49*
– Sankyo Insulin Resistance Project Award 1999 *EASD News Section 10/99 48*
– Scientist Training Course – molecular biology *EASD News Section (1/99) 9 w*
– Study Group – Artificial Insulin Delivery Systems *EASD News Section 8/99 33 w*
– – Epidemiology Group *EASD News Section (3/99) 16*
– – Hypertension in Diabetes *EASD News Section 7/99 30 w*
Eating disorder – type 1 diabetes and A258
Economics of diabetes care A254, A249
– becaplermin treatment of foot ulcer A309
– depression, effect of A54
– early ACE-inhibitor renoprotection A274
– lipid-lowering therapy 1293
Editorial – The world of Diabetologia in 1999 1r
– – *Erratum* 386
Education in diabetes care A254-A257
– diabetic nephropathy risk, effect on A278
– dyslipidaemia A290
– gender, effect of A278
– quality of life and A37
Elastin – metabolism – diabetic children A320
Elderly *[see also* Age*]* – diabetes education A254
– hip fracture in diabetes 920
– lispro biphasic insulin, use of A240
– rosiglitazone therapy A227
Electrogastrography – glycaemic control and – type 1 diabetes A300
Embryo, Fetus *[see also* Birth-weight; Neonate; Malnutrition; Pregnancy; Teratogenesis*]*
– skeletal muscle – GLUT-1 expression A169
Emergency – diabetic – staff training A255
Endoplasmic reticulum – calnexin – insulin receptor processing and 435
Endorphin – acupuncture-induced hypoglycaemia, role in 250
Endothelial, Endothelium 1383r
– antigen – PAL-E – diabetic retinopathy, in 596
– cell – apoptosis – proinsulin and 259c
– – glucose, effect of A34
– – markers – type 1 diabetes – C-reactive protein assn 351
– – proinsulin binding – umbilical vein 259c
– – reperfusion, effect of – diabetes – NO modulation 1350
– – umbilical vein – proinsulin binding 259c
– derived relaxing factor 1383r
– function – circulating markers – diabetes A319-A320
– – diabetes, in A23, A325, A326, A75, A76
– – – duration-dependent 204
– – eye 387r
– – homocysteine and – type 2 diabetes A329
– – metformin, effect of in type 2 diabetes A224
– – offspring of diabetic pregnancy, in – rat 76
– – retina 387r, 1228
– – streptozotocin-diabetic rat 204
– islet – nitric oxide synthase – BB rat diabetes and 457
Endothelin 1383r
– 1 – circulating – macrovascular disease and A320
– – insulin secretion, effect 1302
– polymorphism – diabetic nephropathy and A266
– retinal – streptozotocin-diabetic rat 1228

Energy balance in type 2 diabetes – insulin therapy, effect of 406
Epidemiology – blindness, diabetes-related – time trend A11
– coronary heart disease – diabetes and A279
– diabetes 499r
– – diagnostic criteria, effect of 1168
– – European Group *EASD News Section (3/99) 16*
– – macrovascular disease A48
– – type 1 A74, A75, A83-A89
– – – β-casein variant consumption and 292
– – – early childhood 1055
– – – geographical variation 1395
– – – incidence – Finland 655
– – – registry – EURODIAB – *Erratum* 261
– – – secular trend 655, 1395
– – – urban *vs* rural 789
– – type 2 499r, A105-A113, A43, A44, A5, A60, A61
– – – cardiovascular mortality 297
– – – diagnostic criteria and 647
– – – MODY A114
– diabetic foot ulceration A27
– diabetic nephropathy A277, A278
– diabetic retinopathy A312-A314
– ethnicity – amputation in diabetes A304
– – diabetic nephropathy A277, A278
– – skeletal muscle lipid and abdominal obesity 932
– hypertension – glucose tolerance and A283
– insulin resistance syndrome A60, A61
– isolated post-challenge hyperglycaemia 1050
– macrovascular disease – diabetes A318
– renal cell carcinoma – diabetes as risk factor 107
Erectile dysfunction *[see also* Corpus cavernosum*]*
– α-lipoic acid, effect of – γ-linolenic acid with A292
– penile tactile sensitivity in diabetes 336
– prevalence in diabetes A301
ERK *[see* Kinase – extracellular-signal-regulated*]*
Erythrocyte deformability – diabetes – type 1 865
– laser diffractoscopy 465
– type 1 diabetes, in – C-peptide, effect of 465
EURODIAB study – diabetic retinopathy risk A314
– lipids A285
– neuropathy risk factor s A50
– orthostatic blood pressure response A297
– QTc interval and complications of diabetes 68
– vitamin D supplementation in infancy 51
European Foundation for the Study of Diabetes *EASD News Section 10/99 50*
Exendin-4 – hypoglycaemic action – *db/db* mouse 45
– insulin secretion, effect on – Wistar rat 45, A41
– satiety, effect on – type 2 diabetes A40
Exercise – acute – glycogen stores, effect on – metformin, protection by A225
– – postprandial – glycaemia, effect on in type 2 diabetes 1282
– relatives of type 2 diabetic subjects A113
– training – mortality in diabetes and A5
– – diabetes and A51
– – insulin resistance and 257c
– – skeletal muscle insulin signalling, effect on A178
– – uncoupling protein expression in skeletal muscle and 826
Extracellular matrix – glucose, effect of – ACE inhibitor, modulation by A9
– insulin signalling crosstalk A66

F

FAD-glycerophosphate dehydrogenase – islet – glucocorticoid, effect of A141
– mutant – type 2 diabetes A122
Family – history – diabetes – type 2 – insulin resistance syndrome risk 15
– study *[see also* Twin study*]*
– – diabetes – type 1 – auto-antibody screening A94
– – – – GAD65 antibody A95
– – – – Giessen-Bad Oeynhausen A84
– – – – HLA-DR and islet-cell antibodies 671
– – – – lipoprotein (a) A320
– – – – Th lymphocyte subgroups A63
– – – – type 2 diabetes and nephropathy risk 519
– – – type 2 A112
– – – – ADA *vs* WHO criteria A109
– – – – adipose tissue interstitial lactate A184
– – – – albumin excretion rate 1359
– – – – cardiovascular risk factor s A286
– – – – dyslipidaemia risk 24
– – – – fuel homeostasis in offspring 1314
– – – – glucose effectiveness A164
– – – – hyperglycaemia risk 24
– – – – insulin resistance syndrome A113
– – – – insulin secretion A183, A78
– – – – obesity risk 24
– – – – physical activity A113
– – – – PPARγ polymorphism 758
– – – – skeletal muscle glucose metabolism A167
– – – – type 1 diabetes features A209
– – – – vascular reactivity A325
– – diabetic nephropathy – salt-sensitive blood pressure A284
– – insulin resistance syndrome – quantitative traits A112
Farnesyltransferase – insulin, activation by 310
Fas – insulitis, role in – type 1 diabetes 1332
– polymorphism – type 1 diabetes A90
– serum – diabetic neuropathy, in A51
Fatty acid – essential – diabetic neuropathy and 773r
– – diabetic pregnancy, in A21
– – erythrocyte membrane – diabetic pregnancy A248
– γ-linolenic acid – therapy – α-lipoic acid with A292, A293
– long-chain – vascular smooth muscle, protection of A33
– monounsaturated – postprandial lipoproteins, effect on A289
– non-esterified A205-A208
– – serum – growth hormone infusion, effect of 160
– – – IGF-1 infusion, effect of in rat 160
– – – oscillations – insulin pulsatility and A45
– – fuel homeostasis, role in 128r
– – glycogen synthesis, effect on 1031c
– – insulin secretion, effect on 128r, A153, A204
– – – saturation and A192
– – insulin sensitivity and A45
– – islet toxicity 128r, A143, A144
– – postprandial – offspring of type 2 diabetics 1314
– – vascular reactivity, effect on A77
– ω-3 – dietary – leptin, effect on in sucrose-fed rat A214
– – leptin levels, effect on A194
– synthase – gene – regulation A173
Fenugreek *[see Trigonella foenum graecum]*
Fibrinogen – plasma – insulin resistance syndrome, in A6
– polymorphism – coronary heart disease and, in Chinese diabetics 1250
Fibroblast – skin – type 1 diabetes, function in A9
Fibronectin – tissue-specific – plasma – diabetes A319
FK507 *[see* Tacrolimus*]*
Foot, diabetic A27-A29
– amputation – rate A303-A305, A311
– antibiotic therapy A310
– clinical investigation A304-A307
– epidemiology A303-A305
– foot width A311
– laterality A312
– microbiology A310
– mortality A311
– orthotics A311
– osteoporosis A311
– treatment A306-A309
– ulcer – nitric oxide synthase isoforms, role of 748

Fremantle Diabetes Study A225
Frequency analysis – bivariate – insulin & glucose om IVGTT A79
Friedreich's ataxia – type 2 diabetes associated – genetics A120
Fructose – diet – insulin resistance produced by in rat A215
– metabolism – hepatic A166

G

Gadolinium – islet B-cell, effect on A139
Galectin – 3 – promoter – polymorphism – type 1 diabetes A91
Gastric emptying – cutaneous electrogastrography A50
– diabetes A197
– – euglycaemic hyperinsulinaemia, effect of 365
– diabetic autonomic neuropathy A300, A301
– short-term glycaemia, effect of in type 2 diabetes 1410
Gastroplasty A196
Gender – arterial compliance and 214
– cardiovascular risk factors, effect on – impaired fasting glucose A43
– QTc in diabetes and 68
Gene – expression – islet A149, A150
– mitochondrial – diabetic nephropathy A267
– – hair-follicle sampling 1028c
– – mutation – tRNALys(UUR) 3243 – brain imaging 1266c
– – – – diabetes A122, A123, A140
– – – – insulin sensitivity A183
– – – – heteroplasmy 485, 1438c
– – – – MODY 1131
– – – BHE/cdb rat 35
– – – phenotypic variation – heteroplasmy role 485, 1438 c
– transfection – islet A149
General practice *[see* Primary care*]*
Genetics – confidence intervals for frequencies of rare alleles 635c
– diabetes – autoimmune – heterogeneity 608
– – gestational A79, A80
– – type 1 A73, A74, A90
– – – apolipoprotein (a) 1021
– – – chromosome 2q – Basques 119c
– – – nephropathy risk & familial type 2 diabetes 519
– – type 2 A114-A123, A20
– – – amylin polymorphism A145
– – – β2 adrenoceptor polymorphism 98
– – – BETA2/NEUROD1 480
– – – β_3-adrenoceptor polymorphism 238
– – – family history 15
– – – hepatic nuclear factor polymorphisms 120c, 1011
– – – IRS-2 polymorphism 1244
– – – leptin receptor A5
– – – PAX4 480
– – – Sarco(endo)plasmic reticulum Ca^{2+}-ATPase 1240
– – – skeletal muscle glycogen synthase gene 1138
– – – sulphonylurea receptor polymorphism 617
– – – thrifty genotype 1367r
– – – twin studies 125r, 139, 146
– – – uncoupling protein 2 polymorphism 688
– diabetic microangiopathy – ACE gene polymorphism A326
– diabetic nephropathy 263r, A266, A267
– – aldose reductase polymorphism 94, 1030c
– – β_3 adrenoceptor polymorphism 632c
– – familial type 2 diabetes 519
– – heritability of albumin excretion rate 1359
– – HLA 1017
– – insulin gene 1017
– – methylenetetrahydrofolate reductase 631c
– diabetic retinopathy – AGE receptor polymorphism A12
– dominant negative effect 887
– Lamarckism 257c
– leptin receptor polymorphism A5
– macrovascular disease – lipoprotein (a) A320
– obesity – β_2 adrenoceptor polymorphism 98, 238
– – PPAR-γ2 polymorphism 892
– – uncoupling protein 2 polymorphism 688, 1413
Gila monster *(Heloderma suspectum)* – exendin *[see* Exendin*]*
Glomerular – filtration rate *[see also* Renal – hyperfiltration*]*
– – diabetes A270, A271
– – glucose tolerance deterioration, effect of 90
– hyperfiltration – diabetic nephropathy risk 263r
– – impaired glucose tolerance, in 90
– hypertension – albuminuria in type 2 diabetes and 999
– mesangial cell – cyclin-dependent kinase expression 1425
– N^{ε}-(carboxymethyl)-lysine – diabetic rat 878
– permeability – dextran clearance 263r
– podocyte – microalbuminuria in type 2 diabetes 1341
– ultrastructure – microalbuminuria – diabetes – type 2 A268
GLP-1 (Glucagon-like peptide 1) 373r, A196-A200
– (7–36 amide) – GLUT expression, effect on A170
– – insulin secretion, effect on A39, A40
– – secretion – intestinal A39, A40
– (9–36 amide) – insulin secretion, lack of effect on A198
– glycaemic control, effect on 1148
– inactivation – dipeptidylpeptidase IV – inhibitor A41, A42
– insulin secretion, effect on A78
– insulin-secreting cell, effect on – growth factor 856, A25
– plasma – dipeptidylpeptidase IV inhibitor, effect of in *fa/fa* rat 1324
– receptor A199
– – agonist – exendin-4 *[see* Exendin*]*
– response to glucose load A195
– stimulation test for insulin secretion A153
Glucagon – adipose tissue, effect on A198
– antagonist – BAY27–9955 A42
– secretion – amino acids, regulation by A127
– – amylin, effect of A146
– – dexamethasone-induced insulin resistance, effect of 936
– – endothelin-1, effect of 1302
– – HNF-1α mutation, effect of 621
– – insulin, effect of A200
– – somatostatin, effect of – G proteins, role of A46
Glucagonoma – protein metabolism 326
Glucocorticoid – adipocyte, effect on – GLUT expression A170
– hypoglycaemia counterregulation, role in A70
– insulin resistance induction – islet adaptation 936
– – metformin, effect of A226
– islet, effect on – FAD-glycerophosphate dehydrogenase A141
Glucokinase – anomeric specificity A163
– expression – insulin-secreting cell – glycation, effect of 1417
– insulin secretion, role in – pituitary cell transfection study 498c
– islet B-cell A123
– mutant – islet B-cell, effect on – mathematical model 1175
– polymorphism – hypoglycaemia counterregulation A163
– promoter – hepatic – polymorphism A117
Gluconeogenesis A164-A166
Glucosamine – insulin resistance and A16
Glucose – 6 phosphate – translocase – isoforms A166
– blood – assay – emergency medicine, in A219
– – capillary sampling – abdominal skin A211
– – fasting – diabetes criterion 635c
– – – gastric emptying, effect on 1410
– – meter – laboratory animals, inaccurate in 256c
– – monitoring – device A211
– – – glycaemic control, association with A256

– – – haematocrit, effect of 256c
– – postprandial *[see also* Hyperglycaemia – postprandial*]*
– esters – non-metabolised – insulin secretion, effect on 286r
– fasting – impaired – cardiovascular events and A82
– – – cardiovascular risk factors in A43
– – – insulin secretion in A77
– insulin secretion, effect on – glucotoxicity A148
– – priming A137
– metabolism – hepatic A26, A162-A166
– non-metabolised isomers – esters, insulinotropic effect of 286r
– penta-acetate – insulin secretion, effect on 286r, A40, A128
– tissue – local insulin infusion, effect of A171
– – monitoring – device A211
– – – microperfusion – ionic reference with A64
– – – optical scattering A64
– tolerance – gestational diabetes, following A81
– – hepatic insulin sensitivity, effect of A27
– – heritability – twin study A113
– – impaired *[see also* Diabetes – diagnostic criteria*]*
– – – autonomic neuropathy & hypertension A298
– – – diagnostic criteria 499r
– – – glomerular hyperfiltration 90
– – – insulin secretion in A77
– – – progression to diabetes – intervention study 793
– – – – proinsulin and 177
– – – – renal effect 90
– – lipid tolerance and A286
– – test *[see also* Diabetes – diagnostic criteria*]*
– – – gestational diabetes, predicting A259-A261
– – – isolated post-challenge hyperglycaemia 1050
– – – IV – bivariate frequency analysis A79
– – – – insulin sensitivity measurement 678
– – – – insulin-modified A153
– – – – prandial A186
– – – leptin, confounding by 634c
– – – oral – insulin sensitivity measurement A185
– – – – lipids, acute changes in A207
– toxicity – islet B-cell 1093
– transport – adipocyte – diabetes – type 2 819
– – skeletal muscle – hyperglycaemia, effect of 1071
– – – pregnant rat 802
– – sulphonylurea, effect of 903r
– transporter *[see* GLUT*]*
– turnover – postprandial exercise, effect of – type 2 diabetes 1282
– uptake – brain – hypoglycaemia, during 812
– – C-peptide, effect of – diabetic rat 958
Glucosidase, alpha – inhibitor *[see* Acarbose; Miglitol*]*
Glucotoxicity, islet B-cell – glucokinase gene expression, role of 1417
GLUT (Glucose transporter) A169, A170
– 1 – mesangial cell – Milan glomerulosclerosis-prone rat A273
– – polymorphism – MODY A114
– 2 – insulin secretion, role in – pituitary cell transfection study 498c
– – islet B-cell cytotoxicity, role in A159
– – promoter polymorphism – type 2 diabetes and A119
– 4 – overexpression – human myoblast – insulin sensitivity A16
– – skeletal muscle – hyperglycaemia, effect of 1071
– – translocation – adipocyte – oxidative stress and 949
– – – heart – Rab4 and Rab11, role of A16
Glutamic acid decarboxylase – 65 – homologous peptide I-A^{g7} 560
– islet B-cell expression – heterogeneity 1080
– restricted peptide – immunisation A31
– type 1 diabetes and 3r
Glutathione – aortic – hyperglycaemia, effect of A327
– islet B-cell A155
– peroxidase – endothelial cell – glucose, effect of A34
Glycaemic control – adolescence A209
– cumulative exposure – diabetic retinopathy and A11
– diabetes – type 1 – factors affecting A249
– – – lispro insulin, effect of A239, A240
– – type 2 A220
– – – islet-cell antibodies A81
– – – progression A106
– diabetic nephropathy and 263r, A71
– dietary carbohydrate, effect of – type 1 diabetes A214
– homocysteine levels, effect on – type 2 diabetes A329
– importance 499r
– intensive – insulin resistance syndrome, effect on A222
– lipids, effect on – type 1 diabetes A290
– lispro insulin, effect of A210
– platelet function, effect on – type 2 diabetes A322
– poor – cognitive group training, effect of A38
– short-term – gastric emptying, effect on 1410
– tight – blood pressure during A284
Glycation A57, A58
– advanced end-product – antibodies – diabetic nephropathy A19
– – carboxymethyl-lysine, N^{ε} 603
– – diabetic nephropathy progression and A264
– – diabetic neuropathy, role in 773r
– – diabetic retinopathy, accumulation in 728
– – dietary – endothelial cell, effect on A57
– – inhibitor – 2,3 diaminophenazine 472
– – – growth factors, effect on 579
– – – OPB-9195 579
– – – renoprotection in OLETF rat 579
– – lymphocyte, effect on A101
– – methylglyoxal A327, A328
– – receptor – complications of diabetes, in 1271r
– – – polymorphism – retinopathy A12
– LDL A326
– receptors *EASD News Section 8/99 37*
Glycerol – 1,2,3-tris(methylsuccinate) – metabolism A166
Glycine – receptor – islet B-cell A146
Glycogen – stores – metformin, protection by A225
– synthase – muscle – polymorphism – insulin resistance A116
– – skeletal muscle – polymorphism – type 2 diabetes 1138
– – – pregnant rat 802
– – non-esterified fatty acids, effect of 1031c
– – obesity, in A196
– – prolonged fast, following A162
Glycogenolysis A26, A164, A165
Glycolysis inhibitor – 2-deoxyglucose – insulin-secreting cell, effect on A126
Glycoprotein – PC-1 – polymorphism – diabetic nephropathy and A267
– – – insulin resistance and A20
Glycosaminoglycan – diabetic nephropathy protection by – rat A272
– sulodexide – diabetic foot, effect on A309
– – platelet, effect on A322
– urinary – diabetes A23
G-protein – α-gustducin – islet B-cell, expression in A129
Graves' disease – genetics A74
Green fluorescent protein *[see* Photoprotein*]*
Growth – bone – partial foot amputation, following A28
– craniopharyngioma, following excision of A202
– early response gene 195
– factor – hepatocyte – differentiation induction – MAPK role 450

Growth
– – hepatocyte – insulin resistance and A 24
– – – pancreatic AR42J cell differentiation by 450
– – – proliferative diabetic retinopathy, in A 11
– – – receptor expression – islet B-cell A 150
– – nerve – diabetic rat nerve, expression in – CB1093 effect 1308
– – – receptors 1308
– – platelet-derived – becaplermin *[see* Becaplermin*]*
– – – receptor – deficient mouse A 316
– – retina 870
– – transforming – β – smoking, effect of in diabetes A 320
– – – – mesangial cell, expression in A 272
– – vascular endothelial – expression – glycated albumin effect A 58
– – – glomerular – type 2 diabetes A 273
– – – retina – ACE inhibitor, effect of A 12
– – – vitreous – diabetic retinopathy A 315
– hormone – diabetes – type 1 A 202
– – diabetes – type 2 – GHRP-6, response to A 202
– – human – metabolic effects in normal rat 160
– – insulin-secreting cell, effect on – apoptosis protection A 158
– – releasing hormone A 202
– – releasing peptide 6 A 202
– – therapy – glucose tolerance, effect on A 201
GSH *[see* Glutathione*]*
Gustducin – islet B-cell, expression in A 129
Gymnema sylvestre leaf extract – streptozotocin diabetes, effect on A 233

H

Haem synthase – islet distribution 978
Haematocrit – obesity and A 61
Haemochromatosis, hereditary A 120, A 157, A 221
Haemorrheology – C-peptide and 465
– type 1 diabetes, newly-diagnosed 865
Haemostasis A 47, A 48
– diabetes and A 321, A 322
– diabetic pregnancy A 22
– inhibitors – diabetic heart A 281
– procarboxypeptidase U – diabetes A 23
– serine protease – inhibitor A 281
– tissue plasminogen activator – serum insulin and A 188
– von Willebrand factor – mortality in diabetes and A 72
– – serum insulin and A 188
Hand infection – diabetes – Africa A 312
Harmane – insulin secretion, effect on A 131
HbA1c *[see also* Glycation; Glycaemic control*]*
– filter paper sample A 250
– normal population – mortality and 926
Heart – coronary disease – calcification in diabetes A 59
– – diabetes and A 279-A 281
– – – lipid-lowering therapy, effect of A 18
– – – renal function and A 264
– – genetics – fibrinogen polymorphism 1250
– – polyol pathway, role of – galactose-fed beagle 1404
– – silent – diabetes A 317
– coronary vascular reactivity – insulin, effect of A 172
– – JCR:LA-corpulent rat A 77
– ECG – ambulatory monitoring – diabetes A 294
– – diabetic autonomic neuropathy, in A 294-A 295
– – dobutamine stress A 281
– – QTc – complications of diabetes and 68
– – – diabetes, in 68, A 59
– – – hypoglycaemia, effect of A 71
– – – insulin aspart therapy, during A 237
– – – type 2 diabetes A 295, A 296
– glucose uptake – leptin & insulin, additive effects of A 176
– insulin signalling – streptozotocin-diabetic rat A 67
– K^+_{ATP} channel – sulphonylurea, effect of 845, 903 r
– left ventricular function – diabetes – pancreas transplantation effect A 282
– – thiazolidinedione, effect of A 68
– left ventricular hypertrophy – diabetic nephropathy, in 76
– – diabetic neuropathy and A 302
– – insulin resistance and A 187
– – type 2 diabetes A 60
– microvascular angina – endothelial function A 188
– myocardial infarction – hyperglycaemia in A 283
– – insulin therapy A 282
– rate variability – diabetes 1345, A 295, A 298
Heparin – low-molecular-weight – capillary permeability, effect on in NIDDM 60
Hepatic – fatty infiltration *[see* Hepatic – steatosis; Steatohepatitis, non-alcoholic*]*
– glucose production A 164-A 166
– parasympathetic innervation A 174
– steatosis *[see also* Steatohepatitis, non-alcoholic*]* A 83
Hepatitis – virus *[see* Virus*]*
Hepatocyte – Cynomolgus monkey – culture 41
– growth factor *[see* Growth – factor – hepatocyte*]*
– HTC – pancreastatin, effect of 317
– JAK/Stat pathway – insulin and leptin signalling A 172
– lipoprotein (a) synthesis 41
– nuclear factor – 1alpha polymorphism – African-American DM 380 c
– – MODY *[see also* MODY – 3*]* 1131
– – insulin secretion, effect on 887
– – islet function, effect on 621
– – 1β polymorphism – MODY A 114
– – 4 polymorphism – MODY 1131
– – 6 polymorphism – diabetes and 1011, A 115
– – – insulin secretion and 1011
Heritability – diabetes – type 2 125 r, 139, 146
HGF *[see* Growth – factor – hepatocyte*]*
HID *[see* EASD – Study Group – Hypertension in Diabetes*]*
Hip fracture and diabetes 920
HIV *[see* Virus – human immunodeficiency*]*
HLA – A – persistent islet B-cell function in type 1 diabetes A 74
– B39 – type 1 diabetes A 73
– class I – islet expression – type 1 diabetes, biopsy in 574
– class II – autoimmunity and age associations in type 2 diabetes 608
– diabetic nephropathy and 1017
– DQ – GAD antibody and – type 1 diabetes A 92
– prediction Type 1 diabetes, role in A 84
HMG-CoA reductase inhibitor (Statin) *[see* Lipid – lowering agent*]*
HOMA (homeostasis model assessment) 678, A 185
– pancreas transplantation, following A 217
– CIGMA with immunoreactive insulin 678
Homocysteine, plasma – albumin excretion rate and 382 c
– atorvastatin, effect of A 288
– diabetes, in A 329
– insulin, effect of A 172
HONK *[see* Hyperosmolar non-ketotic coma*]*
Hoorn study – diabetic retinopathy prevalence A 314
– haematocrit and obesity A 61
– homocysteine levels A 329
– mortality – autonomic function A 299
– – hyperglycaemia 926
– – leptin A 106, A 108
– – physical training A 5
Howard Rifkin Award *EASD News Section 9/99 41*
Hydroxyisoleucine, 4 – insulin secretion, effect on A 129

Hyperaldosteronism – primary – insulin resistance A184
Hyperglycaemia – postprandial – gastric emptying, effect on 1410
– – mortality and 1050, A43
– – macrovascular disease and A49
– prolonged – islet B-cell, effect on – amylin accumulation 188
– – islet B-cell, effect on – p21 induction? 1093
– skeletal muscle, effect on – protein kinase C beta$_2$ 1071
Hyperinsulinaemia – cardiovascular risk factor s associated A182
– craniopharyngioma, following excision of A202
– insulin receptor substrate-1 degradation by A67
– insulin signalling, effect on 358
– p21Ras farnesylation, effect on 310
– vascular-cell adhesion molecule secretion unaffected 1235
Hyperlipoproteinaemia – type 1 – lipoprotein lipase mutation A206
Hyperosmolar non-ketotic coma – diabetic – osmoregulation in survivors 534
Hypertension – animal model *[see* Rat – spontaneously hypertensive*]* A285
– diabetes and A283-A285
– – EASD Study Group *EASD News Section 7/99 30 w*
– – mortality 297
– diabetic pregnancy A248
– leptin levels in A193
– treatment – diabetes 263r
– triiodothyronine and A203
Hypertriglyceridaemia – β_2 adrenoceptor polymorphism 98
– diabetes A205
– high fat-fed rat – lipid metabolism in A203
– insulin resistance syndrome, mechanism in A45
– insulin-resistant transgenic rat 419
– masoprocol, effect of – diabetic rat 102
Hypoglycaemia – alcohol, effect of A219
– awareness A69
– – insulin aspart therapy, during A237
– brain metabolism during – fuel uptake 812
– cognitive function, effect on A70, A71
– – long-term A218
– counterregulation A218, A219
– – cortisol A70
– – GLP-1 and A198
– – MODY 2 A163
– GLP-1 action during A198
– management – staff training A255
– neuroglycopenia – caffeine, effect of A219
– nocturnal 1151r, A219
– prevention – type 1 diabetes A256
– sulphonylurea-induced – ACE inhibitor interaction A68
– type 1 diabetes A69
Hypoglycaemic agent – acarbose *[see* Acarbose*]*
– acupuncture 250
– α-glucosidase inhibitor *[see* Acarbose; Miglitol*]*
– aminoimidazole carboxamide riboside A324
– *Averrhoea bilimbi* leaf extract A232
– BAY27–9955 A42
– BRL49653 545
– BTS 67 582 A244
– dipeptidylpeptidase IV inhibitor A41, A42
– exendin 45, A40, A41
– glitazones *[see* Thiazolidinedione*]*
– GLP-1 analogue A199
– glutamate A244
– glycerol-1,2,3-tris(methylsuccinate) A166
– GW1929 545
– *Gymnema sylvestre* extract A233
– imidazoline receptor agonists A131
– isoxazolidinedione – JTT-501 151
– JTT-608 A125, A243
– LG100268 545
– masoprocol 102
– meglitinides *[see* Meglitinide*]*
– metformin *[see* Metformin*]*
– miglitol *[see* Miglitol*]*
– monosaccharide esters, non-metabolised? 286r
– naloxone A69
– nateglinide *[see* Meglitinide – nateglinide*]*
– oral A3
– pioglitazone *[see* Thiazolidinedione – pioglitazone*]*
– PPARγ receptor agonist 545
– repaglinide *[see* Meglitinide – repaglinide*]*
– rexinoid 545
– rosiglitazone *[see* Thiazolidinedione – rosiglitazone*]*
– sulphonylthiourea – 3–15 A243
– sulphonylurea *[see* Sulphonylurea*]*
– troglitazone *[see* Thiazolidinedione – troglitazone*]*
– tungstate A191
– vanadate A243
Hypomagnesaemia – diabetes A154
Hypothermia – insulin secretion, effect on in mouse islets A137
Hypothyroidism – protein metabolism in A164

I

IA-2 *[see* Tyrosine phosphatase – IA-2; Antibody – IA-2*]*
I-A^{g7} *[see* MHC – class II*]*
IAPP *[see* Amylin*]*
IDDM genes – type 1 diabetes in Basques not associated 119c
IGF (Insulin-like growth factor) – 1 – human – metabolic effects in normal rat 160
– – leptin secretion, effect on in normal rat 160
– – mitogenicity – kinase-negative insulin receptor, effect of 763
– – plasma – insulin, effect of A201
– – – type 1 diabetes A201
– – polymorphism A118
– – pregnancy, in A246
– – receptor – aspart insulin, effect of A179
– – – polymorphism A118
– – receptor – Schwann cell A291
– – signalling – mutant insulin receptor, effect of 763
– – vitreous – diabetic retinopathy, in A315
– 2 – thymic expression – BB rat A29
– binding protein – 1 – fetal growth, role in – diabetic pregnancy A22
– – – plasma – insulin, effect of A201
– – 3 – urinary proteolytic activity for – diab nephropathy A274
– – endothelial cell, regulation in A35
IGT *[see* Glucose – tolerance – impaired*]*
Imidazoline – efaroxan A131
– K^+_{ATP} channel inhibitor A130
– receptor A131
Imidazolone-type AGE – diabetic retinopathy, accumulation in 728
Immune – tolerance – HLA match and 1379c
Immunity – innate – cholera toxin B chain, effect of A103-A105
– innate – insulin resistance, role in 497c
Immunoglobulin – G – glycation A58
Immunology – clinical A62, A63, A94-A102
– experimental A7, A29, A103
Incretin response *[see also* Exendin; GLP*]* 373r
– GLP-1 1148c
– hormones – offspring of type 2 diabetic patients 1314
– hyperglycaemic clamp study A79
Infant feeding and type 1 diabetes risk A75
– vitamin D 51
Infection – MRSA – diabetic foot A310
Inflammation – PPARγ and 1033r
– troglitazone, effect of in type 2 diabetes 1433
Information technology – diabetes care – quality monitoring A55
– diabetes information system A55
– diabetic pregnancy outcome prediction A246
– insulin therapy support A251
– telemedicine – diabetes care A250
– – home blood glucose monitoring A64
– – insulin therapy A54
– – retinopathy screening A312

Inositol hexakisphosphate – islet B-cell endocytosis, effect on A 37
Instructions to authors *January & July issues, advertisement pages at front*
Insulin – action A 15
– adipose tissue *vs* skeletal muscle, action on A 171
– analogue 1151 r
– – fast-acting – aspart A 236
– – – – clinical studies A 17
– – – – mitogenic potency A 179
– – – – receptor effects A 178, A 179
– – – lispro A 238, A 239
– – – – biphasic A 240
– – – – glycaemic control, effect on A 210
– – – – immunogenicity A 98
– – – – infusion *vs* injection A 17
– – – – pregnancy, use in A 245, A 260
– – – – renal hyperfiltration, effect on A 278
– – long-acting – fatty-acylated A 235
– – – – NN304 1254
– – – – – free fatty acids, effect of A 17
– – – glargine A 18, A 234, A 235
– aspart *[see* Insulin – analogue – fast-acting – aspart*]*
– assay A 98
– autoantibodies A 94
– – diabetes – type 1 A 92, A 93
– biphasic – lispro/isophane A 240
– expression *[see also* Insulin – gene, Insulin – secretion*]*
– – salivary gland A 148
– – transcription factor – insulin promoter factor 1 A 77
– gene *[see also* Insulin – expression*]*
– – 5' polymorphism (IDDM2) – diabetes – type 1 – Basques A 91
– – diabetes – type 2 A 20
– – diabetic nephropathy and 1017
– – minisatellite – INS VNTR *EASD News Section 6/99 27*
– glargine *[see* Insulin – analogue – long-acting – glargine*]*
– HOE901 *[see* Insulin – analogue – long-acting – glargine*]*
– Humalog *[see* Insulin – analogue – fast-acting – lispro*]*
– immunogenicity – intraperitoneal route A 212
– infusion – continuous with model assessment 678
– – device – EASD Study Group *EASD News Section 8/99 33* w
– – – implantable A 245
– – – mobile 'phone, effect of A 63
– – insulin preparation A 212
– – intraperitoneal A 212
– – metformin therapy, with A 226
– – sc A 212, A 213
– – – glycaemic control, effect on A 63
– – – insulin analogues in 1151 r
– – – lispro insulin A 17, A 239
– inhaled A 232
– isophane – absorption rate – concentration, effect of A 233
– lipolysis, effect on A 53, A 203, A 204
– lipoprotein (a) expression, effect on 41, 897 c
– pharmacodynamics 1151 r
– pharmacokinetics 1151 r
– preparation – storage – temperature control 257 c
– promoter factor 1 A 77
– – polymorphism – functional effects A 114
– prophylactic – NOD mouse A 8
– receptor – expression – aldosterone, effect of A 189
– – expression – diabetes – type 2 358
– – folding – P 193L mutation, effect of 435
– – kinase-negative – IGF-1 mitogenicity enhanced by 763
– – mitogenic – epidermal growth factor chimaera study A 180
– – mutation – compound heterozygous – congenital myopathy 245
– – – P193L – folding, effect on 435
– – processing 435
– – Schwann cell A 291
– – signalling A 66, A 67, A 178
– – – adipocyte – type 2 diabetes 819
– – – cross-talk – pancreastatin 317
– – – pancreastatin, effect of 317
– – – PPARγ A 15
– – – protein tyrosine phosphatase in 1146 c
– – – skeletal muscle – type 2 diabetes A 171
– – substrate – 1 A 66, A 67
– – – – expression in type 2 diabetes 358
– – – – kinase-negative insulin receptor, effect of 763
– – – – polymorphism – gestational diabetes and A 80
– – – – – glucose tolerance and A 175
– – – 2 – expression – pioglitazone, effect of A 182
– – – – mutation – type 2 diabetes A 116
– – – – polymorphism – glucose tolerance and 1244, A 175
– – – 3 – gene – regulation A 20
– – tyrosine kinase – compound heterozygous mutant 245
– – – congenital myopathy 245
– – – knockout mouse 1443 c
– – tyrosine phosphatase A 66
– – peripheral – metformin, effect of A 173
– resistance *[see also* Insulin – sensitivity; Obesity – abdominal*]* 499 r, A 173-A 175
– – acquired autoimmune – IV immunoglobulin therapy 1378 c
– – adipose tissue, role of 1033 r
– – α-lipoic acid-γ-linolenic acid conjugate effect A 173
– – coronary heart disease risk factor 1264 c
– – creatine feeding, induced by A 167
– – cytokine role – evolution and 1367 r
– – diabetes – type 2 15
– – diet-induced – rat A 141
– – endothelial function and A 325
– – – vitamin C, effect of A 328
– – evolutionary perspective 1367 r
– – exercise, effect of A 51, A 52
– – fructose-fed rat A 215
– – gene – CD36 (rat) – human homologue A 118
– – genetics A 20
– – gestational diabetes A 80
– – glucocorticoid-induced – islet adaptation A 146
– – glucose-induced – hexosamine role A 16
– – hereditary hypertriglyceridaemic rat A 16
– – homocysteine and A 329
– – human studies A 182-A 184
– – insulin receptor mutation – P 193L – mechanism 435
– – insulin secretion in A 160
– – insulin secretion pulsatility, effect of A 160
– – interstitial insulin & glucose delivery A 53
– – islet function – dexamethasone, effect of 936
– – isoxazolidinedione, effect of – JTT-501 151
– – large artery, in A 187
– – L-arginine therapy, effect of A 54
– – leptin and A 192, A 193
– – lifestyle, role of – muscular deconditioning role 257 c
– – lipid metabolism A 205-A 208
– – lipoproteins A 205-A 208
– – oxidation-induced – α-lipoic acid protection 949
– – pancreastatin-induced? 317
– – Pima Indians – abdominal obesity and 28
– – PPARγ and 1033 r
– – pregnancy A 160
– – programming *[see also* Malnutrition – early life, in*]* A 245
– – proinsulin level and – type 2 diabetes 1060
– – renal transplantation, following A 154, A 176
– – sensory innervation, role of 260 c
– – severe – lipoatrophy with – muscle lipid metabolism A 183
– – – protein kinase C substrate overexpression A 177
– – skeletal muscle A 167, A 168
– – – physical deconditioning, role of 257 c
– – – intracellular lipid 113, 1171
– – – – *Errata* 386, 1269
– – – – ethnicity 932
– – syndrome 499 r
– – – animal model – JCR:LA-corpulent rat A 77
– – – β_2 adrenoceptor polymorphism 98

– – – epidemiology A 60, A 61
– – – evolution 383 c, 384 c
– – – hyperfibrinogenaemia in A 6
– – – hypertension in – amylin and 1029 c
– – – lifestyle intervention study 793
– – – rat model – PEPCK transgenic 419
– – – skeletal muscle glycogen synthase gene 1138
– – – spontaneously hypertensive X wild rat A 116
– – thermogenesis in – following gestational diabetes A 53
– – tumour necrosis factor α role 1367 r
– – type 2 diabetes families – risk in 24
– – – troglitazone effect A 44
– – vascular reactivity and A 325
– SC injection – dose adjustment A 245
– – lipohypertrophy A 256
– – postprandial – insulin aspart A 238
– secreting cell *[see also* B-cell, islet; Insulin – secretion*]*
– – culture medium, effect of A 126
– – gene – early growth-response – Egr-1 195
– – glucokinase gene regulation – glycation, effect of 1417
– – glucose, effect of – Egr-1 induction 195
– – human – NES 2Y A 132
– – metabolic signalling A 126-A129
– – MIN6 – Egr-1 induction 195
– – phosphatidyl-inositol 3'-kinase – GLP-1 effect 856
– – pituitary adenoma cell, transfected 498 c
– – RIN5AH – BB-rat T-helper cell binding A 7
– – RINm5F – antioxidant enzyme overexpressing 849
– secretion *[see also* Insulin – gene; Insulin – expression; Proinsulin*]* A 160, A 161, A 39-A41
– – K^+_{ATP} channel and 903 r
– – 24-hour profile – offspring of type 2 diabetic patients 1314
– – abdominal obesity and – Pima Indians 28
– – dexamethasone-induced insulin resistance, effect of 936
– – diabetes – type 2 15, A 77-A79
– – dynorphin, role of A 69
– – endothelin-1, effect of – glucagon-mediated 1302
– – exocytosis A 45, A 46
– – – Ca^{2+} microdomains A 65
– – – sulfatide, role of A 30
– – fatty acids, effect of A 204
– – gestational diabetes A 80
– – GLP-1, effect of – diabetes – type 1 *vs* type 2 A 197
– – glucokinase mutants, effect of – mathematical model 1175
– – glucose-stimulated – anomeric specificity A 163
– – – metabolic signalling A 126-A129
– – granule traffic A 35-A37
– – HNF-1α mutation, effect of 621, 887
– – HNF-6 polymorphism and 1011, A 115
– – hormone-sensitive lipase, effect of A 204
– – hyperglycaemia, effect of A 79
– – *in vivo* A 153, A 154
– – individual cell, from – reverse haemolytic plaque assay 1080
– – kinase signalling in A 24
– – leptin, role of A 56, A 57
– – leucine-induced – GK Wistar rat 965
– – methylamine, effect of 233
– – mitochondria, role of A 139-A141
– – modulation A 146-A148
– – MODY-4, in A 77
– – monosaccharide esters, effects of 286 r
– – nitric oxide, role of A 141-A143
– – non-esterified fatty acids, effect of 128 r
– – prediabetes type 2 A 112
– – proinsulin level and – type 2 diabetes 1060
– – proinsulin:insulin ratio 177
– – pulsatility – diabetes – type 2 A 78
– – – glucose oscillation interaction A 79
– – – repaglinide, effect of A 4
– – regulation A 135-A139
– – semicarbazide-sensitive amine oxidase, effect of 233
– – starvation, effect of 128 r
– – tropical diabetes A 191
– semilente – absorption rate – concentration, effect of A 233
– sensitivity *[see also* Insulin – resistance*]*
– – determinants A 173-A175
– – diabetes – type 2 A 77, A 78
– – diabetic nephropathy, in A 272
– – endogenous glucose production and A 186
– – exercise, effect of – postprandial 1282
– – human studies A 182-A184
– – lipids and A 44, A 45
– – measurement 678, A 185, A 186
– – – HOMA A 247
– – – minimal model A 247
– – MODY – 4 A 77
– – pregnancy, effect of – rat 802
– – thyroid and A 203
– – TNFα promoter polymorphism and A 20
– therapy A 17
– – intensive – blood pressure during A 284
– – – hypoglycaemia A 69
– – – myocardial infarction, during A 282
– – metformin, with 406, A 226
– – weight gain during – type 2 diabetes 406
– tolerance test – insulin sensitivity measurement 678
– vascular smooth muscle, effect on 831
– vasodilator effect 493 c, 494 c, 1376 c
Insulitis – biopsy findings and subsequent progression of type 1 diabetes 574
Insulitis – Fas-Fas ligand system involvement – type 1 diabetes 1332
Interferon – α – diabetogenicity A 102
– – type 1 diabetes disease-modifying therapy 385 c
– γ – islet B-cell, effect on 560
– – polymorphism – type 1 diabetes A 90
– regulatory factor – 1 – expression in islet B-cell A 155
– – 2 – polymorphism – type 1 diabetes A 73
Interleukin – 1β – islet B-cell, effect on – cytotoxicity A 14, A 155, A 156
– – – gene expression 1199
– – – MAPKAP kinase-2 role A 124
– 2 – receptor – soluble – diabetes A 101
– 4 – polymorphism – type 1 diabetes A 90
– 8 – serum – diabetes, elevated in 117 c
– 10 – release – type 1 diabetes A 101
– 18 – islet B-cell A 155, A 157
International Textbook of Diabetes Mellitus 901 b
Intestine – GLP-1 (7–36 amide) secretion A 39
– glucose production A 165, A 166
– microsomal triglyceride transfer protein – diabetic rat 944
– small – NOD mouse, in A 7
IPF *[see* Insulin – promoter factor*]*
Ischaemia – skeletal muscle glucose uptake, effect on A 171
Islet – amyloid – human amylin transgenic mouse 1219
– – polypeptide *[see* Amylin*]*
– – transgenic mouse 427
– confocal microscopy 978
– endothelial cell nitric oxide synthase – BB rat diabetes and 457
– function – heterogeneity A 137
– gene expression A 149
– hypothermia, effect of A 137
– immunohistochemistry – NO and CO pathways 978
– innervation – adaptation to induced insulin resistance, role in A 146
– pig – human xenorecognition 330
– pseudo – MIN6 cells A 138
– regulation of hormone secretion A 135
– storage A 139
– tumour – chromosome abnormalities A 149
Isoxazolidinedione – JTT-501 – insulin signalling, effect on 151

J

JNK *[see* Kinase – Jun N-terminal*]*
JTT-501 *[see* Hypoglycaemic agent*]*

K

K^+ channel – inward rectifier 6.2 903r
– inward rectifier 6.2 – mRNA-injected Xenopus oocyte 845
K^+_{ATP} channel – cardiac – sulphonylurea effect 845, 903r
– insulin secretion and 903r
– insulin-secreting cell A130
– islet A-cell A131
– islet B-cell A65
– tissue distribution – differential sensitivity 903r
KANWU study: dietary fat and insulin sensitivity A185, A207
Karlsburg Study – type 1 diabetes risk 661
Keratinocyte – cultured – wound application A307
Ketoacidosis, diabetic – leptin levels and 1067
– management – staff training A255
Kidney *[see* Renal*]*
Kinase – cyclin-dependent – inhibitor – p21 1093
– – mesangial-cell – glucose, effect of 1425
– inhibitor – insulin-secreting cell apoptosis, effect on A158
– insulin receptor *[see* Insulin – receptor – tyrosine kinase*]*
– Janus/Stat pathway – hepatocyte A172
– myosin light chain – insulin secretion, role in A36
– phosphatidyl-inositol – 3' – islet B-cell differentiation, role in 450
– – – expression – type 2 diabetes, in 358
– – – glucagon secretion, role in A200
– – – insulin gene transcription, effect on A24, A25
– – – insulin-secreting cell – GLP-1 effect 856
– – 4' – insulin secretion, role in A45
– phosphoenolpyruvate carboxy – insulin-resistant transgenic rat 419
– protein – B – activation – adipocyte – type 2 diabetes 819
– – B – skeletal muscle – dietary fat, effect of in rat A174
– – C – β – inhibitor – retinal effect in diabetes A12
– – – β – microsatellite polymorphism – type 2 diabetes A119
– – – β_2 – skeletal muscle – hyperglycaemia, effect of 1071
– – – complications of diabetes, role in 1271r
– – – diabetic rat nerve, effect on 1120
– – – embryo, in – glucose, effect of A22
– – – fibroblast – type 1 diabetes A9
– – – inhibitor – diabetic rat nerve, effect on 1120
– – – – serotoninergic transmission, effect on A292
– – – insulin resistance, role in – mechanism A177
– – – insulin secretion, role in 128r, A36, A45
– – – platelet – diabetes A321
– – Ca^{2+}/calmodulin dependent II – diabetic rat brain 693
– – – insulin secretion, role in A25, A35, A136
– – – islet B-cell expression A121
– – extracellular-signal-regulated (ERK) 1271r
– – Jun N-terminal (JNK) 1271r
– – – insulin, activation by A179
– – mitogen-activated – complications of diabetes, role in 1271r
– – – diabetic nephropathy, role in A9
– – – extracellular-signal-regulated 1271r
– – – islet B-cell differentiation, role in 450
– – – islet A25
– – – lipid inhibn of glycogen synth, role in? 1031c
– – – skeletal muscle contraction, effect of A178
– – p38 1271r
– – stress-activated – p63 – islet B-cell A124
– signal-regulated 1/2 *[see* Kinase – protein – mitogen-activated*]*
Krebs cycle – anaplerotic replenishment – islet A126
KvLQT1 channel – insulin-secreting cell, expression in A132

L

Lactate – adipose tissue – interstitial – offspring of type 2 diabetic patients A184
– brain uptake minimal during hypoglycaemia 812
– dehydrogenase – glucose signalling in islet B-cell, effect on A125
– – glucose signalling, effect on A140
– insulin secretion, effect on – LDH-transfected INS-1 cell A128
– serum – metformin, effect of A225
LADA *[see* Diabetes – latent autoimmune in adult*]*
Lamarckism 257c
Lambert-Eaton myasthenic syndrome A95
Larrea tridentata (creosote bush) 102
Laser – diffractoscopy – erythrocyte deformability 465
– foot ulcer debridement A309
Latency-associated peptide – mesangial cell protection A272
Learning disability – diabetes education, effect on A255
Leptin A192-A195
– cardiovascular mortality and A106
– diabetes – type 1 1067
– expression – non-esterified fatty acids and – human 495 c
– hypertriglyceridaemia and – type 2 diabetes A286
– insulin resistance syndrome 499r
– insulin secretion, role in A56, A57
– metformin, effect of – type 2 diabetes with obesity A225
– circulating – insulin therapy, effect of – metformin and 406
– – fasting, effect of – glucose tolerance test, confounding 634c
– – gestational diabetes A79
– – uncoupling protein 2 polymorphism and 688
– pregnancy, in A246
– pulsatility 641r
– receptor polymorphism – glucose tolerance and A21
– – type 2 diabetes and A5
– regulation in man 639r
– secretion – growth hormone infusion, effect of in normal rat 160
– – IGF-1 infusion, effect of in normal rat 160
– signalling – hepatocyte A172
Lipase – hepatic – promoter polymorphism – insulin resistance and A117
– hormone-sensitive – insulin secretion, effect on A204
Lipid, Lipids *[see also* Dyslipidaemia, Fatty acid, Hypertriglyceridaemia, Triacylglycerol*]*
– diabetes, in A18
– hepatic glucose metabolism, effect on A26
– lowering agent – acipimox – insulin secretion, effect on A153
– – acipimox – phospholipid transfer protein, effect on A207
– – atorvastatin A19, A288
– – bezafibrate A68
– – cerivastatin A68, A208
– – diabetes, in – economics 1293
– – fenofibrate – cerivastatin with A208
– – – diabetes, use in A18
– – – vitamin E with – lipoprotein oxidability A289
– – fluvastatin A288
– – statin – diabetes, use in A6
– metabolism A205-A208
– – control – PPARγ 1033r
– – diurnal variation – type 2 diabetes A53
– tolerance – glucose tolerance and A286
Lipoatrophy with severe insulin resistance – muscle lipid metabolism A183

Lipolysis A 53, A 203, A 204
Lipoprotein A 205-A 208
– (a) – expression – insulin, effect of – human relevance? 897 c
– – expression – insulin, effect of 41
– – type 1 diabetes – survival effect 1021
– – – families A 320
– chylomicron – production – streptozotocin-diabetic rat 944
– LDL – glycated – endothelial cell, effect on – LPL modulation A 326
– – oxidation – hyperglycaemia, effect of A 207
– – – insulin, effect of A 172
– – – antibodies – diabetic macrovascular disease A 287
– – size – insulin sensitivity and A 207
– lipase – endothelial cell, effect on A 326
– – mutation A 206
– oxidability – fenofibrate + vitamin E, protection by A 289
– serum – diabetes A 285-A 287
– – diabetic pregnancy A 248
– – pioglitazone, effect of A 227
– VLDL – type 2 diabetes A 285
Lipotoxicity *[see* Fatty acid – non-esterified*]*
– islet B-cell 128 r
Liver *[see* Hepatic, Hepatocyte*]*
Lymphocyte – oxidative stress – NF-κB activation 222
– T – assay – standardisation 636 c
– – autoreactive – diabetes – type 1 443
– – $CD45^+$ – type 1 diabetes 443
– – helper – subgroups – type 1 diabetes families A 63
– – immunoregulatory – diabetes – type 1 443
– – insulin autoreactive – sulphatide, inhibition by 1212
– – subclasses – type 1 diabetes A 99, A 100
– – xenorecognition – pig islet 330

M

Macrophage – PPARγ, role in 1033 r
Macrovascular disease *[see also* Athero. ., Heart – coronary disease, Vascular – disease – peripheral*]* A 48, A 49
– diabetes 499 r, A 317-A 319
– – genetics A 320
– – treatment A 281-A 283
– C-reactive protein and – type 1 diabetes 351
– early marker – arterial distensibility 987
– endothelin, role of 1383 r
– experimental – aldose reductase inhibitor, effect of 1404
– impaired fasting glucose, in A 82
– mortality – type 2 diabetes 297
– renal – type 2 diabetes A 268
Magnesium – erythrocyte – diabetes A 154
Magnetic resonance – imaging – brain – diabetes A 291
– imaging – brain – severe hypoglycaemia A 71
– – spectroscopy – skeletal muscle lipid 113, A 52
– – – *Errata* 386, 1269
Malnutrition in early life – adipocyte, effect on A 15
– B-cell, islet, effect on – ageing, modulation by 711
– catecholamine metabolism in 2nd generation A 190
– diabetes – type 2 – twin study 898 c
– insulin resistance syndrome – weight gain and A 61
– islet B-cell, effect on A 14
– islet, effect on – second generation offspring A 144
– leptin-insulin interactions following A 194
Malonyl CoA – insulin secretion, role in 128 r
Mannoheptulose – hexa-acetate – insulin secretion, effect on 286 r
MAPK *[see* Kinase – protein – mitogen-activated*]*
Masoprocol – metabolic effects in fat-fed streptozotocin-diabetic rat 102
Maternally-inherited diabetes – BHE/cdb rat 35
– with deafness – genetics A 122
– mitochondrial function 485
– mtDNA heteroplasmy 1438 c
– prevalence 1028 c
Mathematical model – CIGMA 678
– HOMA 678, A 185, A 217
– insulin secretion – IVGTT A 153
– insulin sensitivity – pregnancy A 247
– islet B-cell glucose sensing – glucokinase mutants 1175
– type 1 diabetes incidence 1395
Maturity-onset diabetes in youth *[see* MODY*]*
Meglitinide – nateglinide 903 r, A 4, A 241
– repaglinide A 241, A 242
Melanocyte stimulating hormone – insulin resistance and A 195
Melatonin – chronobiology – diabetes A 299
– islet B-cell cytotoxicity, effect on A 156
Meta-analysis – rising incidence of type 1 diabetes 1395
Metabolic syndrome *[see* Insulin – resistance – syndrome*]*
– X *[see* Insulin – resistance – syndrome*]*
Metformin A 224-A 226
– contraindications A 3
– exercise, interaction with A 52
– islet transplantation, effect on outcome following A 33
– islet, effect on – lipotoxicity protection A 144
– mechanisms of action A 173
– sulphonylurea with – mortality in diabetes and A 3
– therapy – insulin, with 406
– – miglitol, with A 223
– – thiazolidinedione, with A 230
Methylamine – oxygen free radical generation, role in 233
Methylenetetrahydrofolate reductase polymorphism – diabetic complications 631 c, A 329
Methylglyoxal – circulating – postprandial A 327
– urinary – diabetes A 328
MgADP – K^+_{ATP} channel and 903 r
MHC (Major Histocompatibility Complex) MHC *[see also* HLA*]*
– class II – $I\text{-}A^{g7}$ – NOD mouse T-cell activation by 560
Microalbuminuria – beta-blocker therapy – renal histology 589
– diabetes – type 2 – renal biopsy A 268
– ACE inhibitor therapy – renal histology 589
– angiotensin converting enzyme inhibitor therapy A 10
– antihypertensive therapy – renal histology 589
– assay 263 r
– cardiovascular risk factor – diabetes A 317
– diabetes, in A 270-A 271
– – mortality – von Willebrand factor and A 72
– – renal biopsy 589
– diabetic nephropathy, progression to A 71, A 73
– endothelial function in A 76
– homocysteine levels and A 329
– hyperproreninaemia preceding 1006
– – *Erratum* 1446
– implications 263 r
– nitric oxide, plasma – type 1 diabetes A 323
– progression – podocyte number predicting 1341
– rosiglitazone, effect on in type 2 diabetes A 230
– screening – albumin/creatinine ratio A 271
– vascular reactivity and A 76
Microangiopathy, diabetic – semicarbazide-sensitive amine oxidase role 233
Microbiology – diabetic foot A 310
Microvascular function *[see also* Capillary; Microangiopathy; Vascular – reactivity*]*
MIDD *[see* Maternally-inherited diabetes with deafness*]*
Miglitol A 223
Mineralocorticoid – insulin receptor expression, effect on A 189
Minkowski Prize 1999 – R Scharfmann *EASD News Section 10/99 43*

Mitochondria, Mitochondrial – diabetes – BHE/cdb rat 35
– function – mitochondrial gene mutation, effect of 485
– islet B-cell A139-A141
Mobile 'phone – insulin infusion pump, effect on? A63
MODY – 2 – glucose homeostasis – mathematical model 1175
– – hypoglycaemia counterregulation A163
– 3 – African-American children 380c
– – HNF-1α mutation & islet function 621
– – mechanism 887
– – metabolic study A78
– 4 A77
– genetics 121c, 1131, A114, A115
Monocarboxylate transporter type 1 – retinal angiogenesis and 870
Monosaccharide esters 286r
Morgagni medal – Dr E Ferrannini News Section 1/99 12
Mortality – cardiovascular – diabetes – type 2 297
– – endstage renal disease in NIDDM A264
– – hyperglycaemia and 926
– diabetes – diabetic foot A311
– – elderly A299
– – exercise and A5
– – infectious diseases – Chad A210
– – insomnia and A221
– – nephropathy – intensive insulin therapy A72
– – QTc prolongation and – nephropathy, effect of A296
– – sulphonylurea with metformin and A3
– – type 2 297
– – von Willebrand factor and A72
– hyperglycaemia – normal population, in 926
– isolated postprandial hyperglycaemia A43
– myocardial infarction – diabetes, effect of A317
– postprandial hyperglycaemia and 1050
Mouse – *db/db* – rosiglitazone with $\beta_3$adrenoceoptor agonist treatment A181
– – islet B-cell failure – PPARγ receptor agonist, effect of 545
– – islet B-cell failure – rexinoid therapy, effect of 545
– – neuropathy 773r
– – rosiglitazone with $\beta_3$adrenoceptor agonist, effect of A181
– HU-PBL-SCID immunodeficient – islet transplantation A104
– insulin-receptor-kinase knockout 1443c
– NOD – cytokines, circulating – insulitis marker A104
– – experimental immunology A7
– – immune tolerance induction – I-A^{g7} 560
– – islet B-cell – troglitazone, effect of A94
– – phogrin autoimmunity A103
– – T-cell function – troglitazone, effect of A103
– – T-cell-activating peptide – I-A^{g7} and GAD-65 560
– – thymic medulla, structure of A29
– normal – glucose disposal A168
– *ob/ob* – glucose 6-phosphatase, islet – leptin, effect of A57
– – human amylin transgenic – diabetogenesis 427
– PDGF-BB knockout – retinal pericyte function A316
– RAG-2 knockout – NIDDM induced by EMC virus A103
– transgenic – HLA-DR3/huCD4 – GAD immunisation in A31
– – human amylin – amyloid formation 1219
– – – diabetogenesis 427
– – interferon-γ expressing – rat glucagon promoter 560
Muscle – skeletal – carbohydrate metabolism A167, A168
– – contraction – kinase activation A178
– – deconditioning – insulin resistance, role in 257c
– – eccentric exercise, damage by – insulin resistance A175
– – glucose transport – pregnant rat 802
– – GLUT – 1 – gestational age and A169
– – – 4 – age, effect of A169
– – insulin action A171
– – insulin resistance A15
– – insulin signalling – fibre type specificity A178
– – – JTT-501, effect of 151
– – interstitial fluid – insulin & glucose in type 2 diabetes A53
– – intracellular lipid – insulin sensitivity and 113
– – – insulin sensitivity and – *Errata* 386, 1269
– – K^+_{ATP} channel – sulphonylurea, effect of 903r
– – leptin levels, effect on A192
– – lipid, insulin resistance and 1171
– – – ethnicity 932
– – lipolysis – insulin, regulation by 1171, A53
– – phosphorylation – pregnant rat 802
– – protein kinase C – β_2 – hyperglycaemia, effect of 1071
– – thiazolidinediones, effect of A180
– – uncoupling protein expression – obesity and 302
– – – physical activity and 826
– smooth, vascular – human – insulin, effect of 831
– – K^+_{ATP} channel – gliclazide, effect of 845
– – lipoprotein lipase, effect of A33
– – nitric oxide synthase – insulin activation 831
Myopathy – congenital fibre-type disproportion – insulin receptor mutation 245
Myosin – insulin secretion, role in A36

N

NADP(H):quinone oxyreductase – polymorphism – type 1 diabetes A90
Nat Acad Sci (USA) – election of Dr L Orci EASD *News Section 1/99 12*
Nateglinide *[see* Meglitinide – nateglinide*]*
Natriuretic peptide – atrial – plasma – diabetic retinopathy A315
– – polymorphism – diabetic nephropathy A267
– brain – albumin excretion rate, effect on in diabetes A271
– – plasma – diabetic retinopathy A315
Neonate – diabetes A212
– overweight – insulin & growth hormone levels A21
Nephropathy, diabetic 263r, A9, A71, A72
– advanced glycation end-products, role of 878
– AGE antibodies in A19
– AGE inhibitor, protection by – OLETF rat 579
– erythropoietin-deficient anaemia A278
– genetics – β_3 adrenoceptor polymorphism 632c
– – familial type 2 diabetes 519
– – HNF-1β A114, A115
– – methylenetetrahydrofolate reductase 631c
– glomerular hypertension, role of 999
– hypertension management A284
– left ventricular hypertrophy in 76
– mitogen-activated protein kinase role 1271r
– morphology A268
– oxidative stress 222
– pathogenesis 263r, A272-A274
– – glucose and tubulointerstitial cell 1113
– podocytes 1341
– prevention 263r
– progression 263r, A184
– quality of life A258
– risk factors 263r, A263-A265
– tetraploid cells and 118c
– treatment A274-A276
Nerve – blood flow – microlightguide spectrofluorimetry 737
– electrophysiology – diabetes A291
– function – newly-diagnosed diabetes, in A290

Nerve
– – diabetic rat – aminoguanidine, effect of 743
– ischaemia – microlightguide spectrophotometry in man 737
– islet A146
– metabolism – diabetes – sorbitol dehydrogenase inhibitor, effect of 1187
– Na^+/K^+ ATPase – aminoguanidine, effect of – diabetic rat 743
– protein kinase C, effect of – streptozotocin-diabetic rat 1120
– regeneration – diabetes. effect of – BB rat A291
– Schwann cell – insulin & IGF-1 receptors A291
– sensory – insulin sensitivity, effect on 260c
– thrombomodulin expression – diabetic rat – aminoguanidine effect 743
Neuropathy *[see also* Complications of diabetes; Nerve*]*
– diabetic – aldose reductase inhibitor A43
– – animal models 773r
– – assessment 336
– – autonomic – baroreflex function A296, A297
– – – cardiac A59
– – – clinical investigation A294-A300
– – – cutaneous electrogastrography A50
– – – gastrointestinal A300, A301
– – – pancreas transplantation, effect of A32
– – – pulmonary – MIBG scintigraphy A50
– – – small-fibre A301, A302
– – baropedograhy A305
– – CB1093, protection by – nerve growth factor role 1308
– – clinical management 902b
– – cytokines in – α-lipoic acid, effect of A102
– – disability score – foot ulceration, prediction of A27
– – general aspects A290-A292
– – microvascular role 737
– – mitogen-activated protein kinase role 1271r
– – orthostatic responses A297, A298
– – osteoporosis and A311
– – pain A42
– – pathogenesis 773r, A42, A43
– – penile tactile sensitivity 336
– – prevention – sorbitol dehydrogenase inhibitor? 1187
– – protein kinase C role 1120, 1271r
– – risk factor A50, A51
– – streptozotocin-diabetic rat 1308
– – treatment A292-A294
– – type 1 *vs* type 2 diabetes 773r
– experimental 773r
Neuropeptide – pancreastatin 317
– Y – polymorphism – atherogenesis A318
– – *Psammomys obesus*, effect on A193
Neurotrophins 773r
Neutrophil – deformability – diabetes – type 1 865
NF-κB *[see* Transcription factor – NF-κB*]*
Nicorandil – K^+_{ATP} channel, effect on A130
Nicotinamide – dithizone diabetes in rabbit, effect on A93
– islet B-cell cytotoxicity, effect on 55
– type 1 diabetes disease-modifying therapy A82
Niflumic acid – insulin secretion, effect on A136
Nitric oxide – vascular reactivity, role in – streptozotocin-diabetic rat 204
– complications of diabetes and A323, A324
– endothelial cell permeability response to glucose, role in A34
– erectile function and – diabetes 343
– insulin secretion, role in A141-A143
– islet B-cell cytotoxicity – oxygen free radicals, synergy with 849
– platelet Ca^{2+} signalling, effect on 167
– synthase – endothelial – diabetes – type 2 A76
– – expression – islet B-cell A155
– – glomerular – diabetic rat 878
– – inducible – platelet – diabetes, in 539
– – insulin-secreting cell A141-A143
– – islet distribution 978
– – islet endothelium – BB rat, abnormal in 457
– – isoforms – diabetic foot ulcer, role in 748
– – polymorphism – diabetic nephropathy A266
– – vascular smooth muscle – insulin activation 831
Nitroarginine – vascular reactivity, effect on – streptozotocin-diabetic rat 204
N-methyl-D-aspartate expression – streptozotocin-diabetic rat brain 693
NMR spectroscopy *[see* Magnetic – resonance – spectroscopy*]*
NSAID (Non-steroidal anti-inflammatory agent)
– insulin secretion, effect on – type 2 diabetes A153
Nuclear – factor – hepatocyte *[see* Hepatocyte – nuclear factor*]*
– receptor – PPAR 1033r
– – retinoid X 1033r
Nutrition A213-A215
– insulin resistance, role in A46
– parenteral – islet function, effect on A143, A144
– prolonged fasting – glucose disposal, effect on A162

O

Obesity *[see also* Satiety*]*
– abdominal *[see also* Insulin – resistance*]*
– – arterial compliance and 214
– – assessment – ultrasound A208
– – diabetes – adolescence A208
– – dyslipidaemia and – glucose tolerance test, in A207
– – genetics – UCP-3 polymorphism A117, A119
– – lipoproteins and – type 1 diabetes A285
– – Pima Indians 28
– – plasminogen activator inhibitor expression and A48
– – skeletal muscle lipid and – ethnicity 932
– craniopharyngioma, following excision of A202
– diabetes – type 2 – mortality 297
– genetics – β2 adrenoceptor polymorphism 98
– – PPAR-γ2 polymorphism 892
– gestational diabetes and A79, A80
– glucose tolerance in – ADA *vs* WHO criteria A111
– IGT with – lifestyle intervention study 793
– insulin-resistant transgenic rat 419
– leptin and A192-A195
– thiazolidinedione therapy in A228
– treatment – gastroplasty A196
– – hypocaloric diet – lipid oxidation rate, effect of A204
– – orlistat A47, A47, A215
– type 2 diabetes risk 15
– uncoupling protein 2polymorphism and 1413
– uncoupling protein isoforms in A206
– uncoupling protein-3 expression 302
Oestrogen – replacement – insulin resistance, effect on A182
Okadaic acid – glucose uptake, effect on – adipocyte – type 2 diabetes 819
Orexin – expression – obese animal models A194
Orlistat *[see* Obesity – treatment*]*
Orthotics *[see also* Foot – diabetes*]*
Orthotics A308
Osmolality – skeletal muscle glucose metabolism, effect on A168
Osmoregulation – HONK survivors, in 534
Osteoporosis *[see also* Bone – density*]*
– diabetes and 920
– diabetic foot A311
Oxidase – amine – semicarbazide-sensitive – plasma – diabetes 233
Oxidative stress – B-cell, islet A139
– complications of diabetes, role in 1271r, A327, A328
– diabetes – semicarbazide-sensitive amine oxidase role 233
– – type 2 – vitamin supplements, effect of A281
– diabetic nephropathy, role in 222, A273
– diabetic retinopathy, role in 728, 773r
– DNA damage – complications of diabetes and 995

Oxidative stress
– gender, effect of – type 1 diabetes A 49
– LDL – insulin, effect of A 172
– marker – 4-hydroxyalkenals – retina A 12
– – lymphocyte NF-κB activation 222
– postprandial A 328
– – lispro insulin, effect of A 240
Oximetry – microlightguide spectrophotometry – human sural nerve 737
Oxygen – free radicals – generation – diabetes 233
– – glucokinase gene expression, effect on 1417
– – islet B-cell cytotoxicity – defence mechanism A 13
– – – nicotinamide, effect of 55
– – – nitric oxide synergy 849
– – platelet, effect on – Ca^{2+} signalling 167
– – superoxide – platelet 167
– hyperbaric A 308

P

p21 *[see* Kinase – cyclin-dependent – inhibitor]
p21Ras – farnesylated – hyperinsulinaemia, effect of 310
p75NTR – nerve growth factor receptor 1308
PACAP *[see* Pituitary – adenylate cyclase activating polypeptide*]*
PAI *[see* Plasminogen – activator – inhibitor*]*
Pancreas – B-cell *[see* B-cell, islet*]*
– biopsy – type 1 diabetes 574, 1332
– carcinoma – tumour marker A 82
– cell line – AR42J – differentiation to endocrine cell 450, 719
– duct cell – differentiation to endocrine cell A 150
– exocrine – cell – differentiation to endocrine cell A 150, A 151
– – function – type 2 diabetes, in A 82
– islet *[see* islet*]*
– perfused – rat – leptin, effect of A 56
– peripheral venous diversion – insulin resistance induced by A 174
Pancreastatin – insulin signalling, effect on 317
Pancreatic – polypeptide – expression – pancreatic acinar cells A 151
Pancreatitis – recurrent severe – lipoprotein lipase mutation A 206
Pancreatitis – tropical calcific A 191
PAX4 *[see* Transcription factor*]*
PC-1 *[see* Glycoprotein – PC-1*]*
Pentose phosphate pathway – embryo – high glucose, effect of A 247
Perforin – EMC-virus-induced diabetes in mouse, role in A 103
Pericyte, retinal – impaired – heterozygous PDGF-BB knockout mouse A 316
Peroxisome proliferator-activated receptor γ (PPARγ) 1033 r
– adipocyte, role in A 15
– co-activator A 207
– cytokines, effect of 702
– knockout mouse A 15
– polymorphism – type 2 diabetes 758
– receptor – agonist 545
– thiazolidinedione on 702
– 2 – human adipose tss 495 c
– 2 – polymorphism 892
– natural ligands A 182
Peroxynitrite – inducible-nitric-oxide-synthase-dependent – diabetic platelet 539
Phaeochromocytoma-cell differentiation – Bsk/lyk-induced A 151
Phensuccinal *[see* Antioxidant*]* A 233
Phenylalanine hydroxylation – glucagonoma, effect of 326
Phogrin (phosphatase on the granule of insulinoma) A 65, A 135
Phosphocreatine – islet B-cell function and A 138
Phosphodiesterase – inhibitor – JTT-608 A 125
Phosphoinositol glycans – insulin receptor substrate-1, effect on A 66
Phospholipid transfer – protein A 207, A 208
– phogrin *[see* Phogrin*]*
Photoprotein – green fluorescent protein – insulin exocytosis marker A 36
– – phogrin chimaera A 65
– – pH-sensitive A 135
Phrenic nerve function – type 1 diabetes A 290
Pig – pathogen-free – retrovirus type C mRNA A 216
Pima Indians – abdominal obesity 28
– diabetes – childhood – GAD antibodies 1265 c
– glomerular filtration rate – glucose tolerance and 90
– type 2 diabetes – microalbuminuria – podocytes 1341
Pineal gland – calcification A 299
Pioglitazone *[see* Thiazolidinedione – pioglitazone*]*
Pituitary – adenylate cyclase activating polypeptide – insulin secretion and A 147, A 148
– – receptor – antagonist A 40
– cell – transfected – proinsulin A 148
PKC *[see* Kinase – protein – C*]*
Plasminogen activator inhibitor – expression A 47
– islet cell migration, role in A 152
– promoter – polymorphism – retinopathy A 316
– urinary – diabetes A 23
Platelet – Ca^{2+} signalling – diabetes 167
– function – diabetes A 321
– nitric oxide synthase – inducible – diabetes, present in 539
– peroxynitrite production – diabetes 539
– protein kinase C – thrombin, activation by – diabetes A 48
Poly(ADP-ribose) synthetase – islet B-cell cytotoxicity, role in A 8
Polycystic ovary syndrome – insulin secretion – lipid *vs* glucose-stimulated A 162
Polymerase chain reaction – allele-specific amplification 35
– competitive 35
– reverse-transcription competitive 358, *EASD News Section (5/99) 23*
Polyol pathway – complications of diabetes 773 r, 1271 r
Positron emission tomography – painful diabetic neuropathy A 42
PPARγ *[see* Peroxisome proliferator-activated receptor γ*]*
Pramlintide *[see* Amylin – analogue – pramlintide*]*
Prediabetes – type 1 – islet-cell antibodies in infancy 671
– – islet-cell associated antibodies – IgG subclasses A 95
– type 2 *[see also* Family study – diabetes – type 2*]*
– – insulin secretion A 112
Prediction – diabetic microangiopathy – N^{ε}-(carboxymethyl)-lysine 603
– gestational diabetes A 259
– latent autoimmune diabetes in adult – islet autoantibodies 840
– microalbuminuria – hyperproreninaemia and HbA1c – *Erratum* 1446
– – hyperproreninaemia and HbA1c 1006
– type 1 diabetes 3 r, A 93, A 84
– – infancy 671
– – islet auto antibodies – neonatal 181, 1375 c, 1445 c
– – Karlsburg study 661
– – secular trend in incidence 1395
– type 2 diabetes – obesity + family history 15
– – parity A 106
– – proinsulin:insulin ratio 177
Pregnancy – BB/OK rat – maternal diabetes affecting genotype of offspring A 74
– diabetes *[see also* Diabetes – gestational*]* A 21-A 22, A 245-A 249
– – adhesion molecule expression in A 102
– – vascular function in offspring – rat 76
– glucose transport in – rat skeletal muscle 802
– IGF-1 A 246
– insulin kinetics A 160
– insulin resistance – skeletal muscle glucose uptake 802
– leptin A 246
Presenilin 2 – insulin-secreting cell, presence in A 134
Primary care – diabetes A 252-A 254

Procarboxypeptidase U A 23
Proinsulin – C-peptide *[see* C-peptide*]*
– endothelial cell, effect on 259 c
– insulin, ratio to – progression from IGT to diabetes and 177
– plasma – cardiovascular risk factor A 5
– – insulin secretion and – type 2 diabetes 1060
– secretion – diabetes – type 2 A 154
– – gestational diabetes A 80
Prolactin – insulin-secreting cell, effect on – apoptosis protection A 158
Prorenin, serum – microalbuminuria, preceding 1006
– – *Erratum* 1446
Protease inhibitor – indinavir – insulin signalling, effect on A 179
– metabolic effects A 221
Protein – acute-phase – troglitazone, effect on in type 2 diabetes 1433
– binding – insulin detemir A 236
– G *[see* G-protein*]*
– green fluorescent *[see* Photoprotein*]*
– kinase *[see* Kinase – protein*]*
– metabolism – glucagonoma 326
– – hypothyroidism, in A 164
– tyrosine phosphatase – insulin signalling, role in 1146 c
Psammomys obesus – insulin resistance – age, effect of A 175
– leptin, effect of A 193
– neuropeptide Y, effect of A 193
Psychological aspects of diabetes care *[see* Diabetes – care – psychological aspects*]*
Pyruvate – brain uptake minimal during hypoglycaemia 812
– methyl – insulin secretion, effect on A 140

Q

Quality of life – assessment – WHO-QOL-100 questionnaire A 257
– diabetes and A 37, A 38, A 257, A 258
– – type 1 – adolescence A 81
– – type 2 – repaglinide, effect of A 242
– insulin aspart therapy A 237
Quality standards in diabetes care *[see* Diabetes – care – quality assurance*]*

R

Rabbit – dithizone-induced diabetes – nicotinamide effect A 93
– – phensuccinal effect A 233
Radiation, ionising, environmental exposure to – glucose tolerance, effect on A 159
Ras proteins – post-translational modification – hyperinsulinaemia, effect of 310
Rat – BB – acupuncture-induced hypoglycaemia 250
– – diabetes – diet, protection by A 93
– – – islet endothelial-cell nitric oxide synthase 457
– – diabetes-prone – islet Fas expression A 104
– – experimental immunology A 7
– – islet B-cell apoptosis A 13
– – islet B-cell cytotoxicity – diazoxide, protection by A 8
– – neuropathy 773 r
– – renal hypertrophy – diabetes 1425
– – thymus – insulin-like peptides, expression of A 29
– BB/OK – diabetic – spontaneously hypertensive hybrid A 285
– – maternal diabetes – genotype of offspring, effect on A 74
– BHE/cdb – mitochondrial diabetes 35
– dexamethasone-treated A 214
– fructose-fed – sympathetic nervous system, effect on A 215
– Goto-Kazikaki (GK) – diabetes – genetics A 118
– – insulin secretion 965
– – islet B-cell growth & regeneration 1098
– hereditary hypertriglyceridaemic – malonyl CoA fuel sensing A 16
– JCR:LA-corpulent – coronary vascular reactivity A 77
– Milan – hypertensive A 273
– – normotensive, glomerulosclerosis-prone A 273
– Otsuka Long Evans Tokushima Fatty – nephropathy 579
– spontaneously hypertensive – BB/OK diabetic hybrid A 285
– – wild rat hybrid A 116
– streptozotocin-diabetic – acupuncture-induced hypoglycaemia 250
– – advanced glycation end-products 472
– – aminoimidazole carboxamide riboside effect A 328
– – C-peptide I & II effects 958
– – endothelial function 204
– – fat-fed – masoprocol, effect of 102
– – neuropathy 773 r
– – offspring, vascular function in 76
– – vascular hypertrophy 472
– transgenic – insulin-resistant phosphoenolpyruvate carboxykinase 419
– Zucker *fa/fa* – dipeptidylpeptidase IV inhibitor, effect of 1324
– – glucose homeostasis – lithium, effect of A 168
– – orexin expression A 194
Receiver operator characteristics curve analysis 647
Redox balance, cellular – diabetic nephropathy A 274
Renal *[see also* Glomerular, Microalbuminuria, Nephropathy, Urine*]*
– artery – stenosis – diabetes – type 2 A 268
Renal – biopsy – diabetes – type 2 A 268
– – diabetic nephropathy – prognostic value A 72
– – microalbuminuric type 1 diabetic patients 589
– carcinoma – diabetes, increased risk in 107
– failure – chronic – diet in A 213
– function – diabetes A 270
– haemodynamics – albuminuria, in 999
– hyperfiltration – postprandial – lispro insulin, effect of in NIDDM A 278
– hypertrophy 263 r
– – ACE inhibitor, effect of A 10
– – – mechanism in BB rat 1425
– impairment – pioglitazone pharmacokinetics A 229
– – repaglinide pharmacokinetics A 242
– loop of Henle – Na^+/K^+ ATPase – streptozotocin-diabetic rat A 270
– macrovascular disease – type 2 diabetes A 268
– plasma flow – diabetes – type 2 A 270
– protection 263 r, 1425
– proximal tubule cell – intermittent high glucose, effect of 1113
– transplantation *[see* Transplantation*]*
Renin – hyperproreninaemia preceding microalbuminuria 1006
– – *Erratum* 1446
– plasma – posture, effect of – diabetes A 23
Repaglinide *[see* Meglitinide – repaglinide*]*
Reperfusion – endothelial cell, effect on – diabetic rat 1350
Respiration – islet – glucose stimulation, during A 126
Retina – blood flow -streptozotocin-diabetic rat 1228
– cultured explant – angiogenesis 870
– endothelial function – streptozotocin-diabetic rat 1228
Retinoid X – receptor – agonist *[see* Rexinoid*]*
Retinopathy, diabetic A 11
– aldose reductase inhibitor, effect of – rat A 276
– angiotensin converting enzyme inhibitor, effect of A 278
– capillary permeability – endothelial PAL-E exprn 596
– endothelial function 596
– epidemiology A 312-A 314
– genetics – aldose reductase A 120
– haemodynamics 387 r
– microaneurysm, role of 1107
– mitogen-activated protein kinase role 1271 r
– mortality and A 72
– pathogenesis 387 r, A 315
– pathophysiology 387 r
– photocoagulation, effect of – angiostatin role A 11
– pregnancy, effect of A 249
– progression – microaneurysm, predictive role of 1107

Retinopathy, diabetic
– protein kinase C involvement 1271r
– risk – N^{ε}-(carboxymethyl)-lysine 603
– screening A312, A313
– thrombin generation abnormality A321
– treatment A315-A317
Retrovirus *[see* Virus*]*
Reverse haemolytic plaque assay – insulin secretion by individual cell 1080
Rexinoid (retinoid X receptor ligand)
– *db/db* mouse, effects in – PPARγ receptor agonist, with 545
– uncoupling protein expression, effect on A206
Rilmakarin – K^{+}_{ATP} channel, effect on A130
Rosiglitazone *[see* Thiazolidinedione – rosiglitazone*]*

S

Salivary gland – insulin expression in A148
Sarco(endo)plasmic reticulum Ca^{2+}-transport ATPase – gene – type 2 DM 1240
Satiety – exendin-4, effect of A40
Scandinavian Simvastatin Survival Study – lipid-lowering therapy economics 1293
Scintigraphy – ^{123}I-MIBG aerosol – diabetic autonomic neuropathy A50
Screening – carcinoma of pancreas A82
– coeliac disease 1195, 1441c
– diabetes 499r
– diabetes risk – type 1 661
– diabetic retinopathy A312, A313
– gestational diabetes A261
– maternally-inherited diabetes with deafness 1028c
– microalbuminuria A271, A272
– mutation – allele-specific amplification 35
– – single-strand conformational polymorphism 1240
Selectin – P – endothelial cell expression – reperfusion – diabetes 1350
Semicarbazide-sensitive amine oxidase *[see* Oxidase*]*
Serotoninergic neurotransmission – diabetic rat A292
Sheer force – diabetic foot A28
Sheffield Prospective Diabetes Study A50
Sialic acid *[see* Vascular – inflammation*]*
Silicone – foot ulcer application A309
Single-photon emission tomography – myocardial perfusion A280
Skin – advanced glycation end-products – assay A58
– blood flow – diabetes A306
– culture
– cultured preparation – wound healing, effect on A28
– sympathetic response – type 2 diabetes A301
Sleep – disturbance – diabetes A221
Smad proteins – islet B-cell differentiation, role in 719
Smoking – DNA oxidation 995
– dyslipidaemia, effect on in type 2 diabetes A287
– lipid peroxidation, effect on A320
– transforming growth factor-β levels, effect on A320
Socio-economic state – diabetes risk factor A6
– glycaemic control, effect on – adolescent diabetes A38
– infancy – type 1 diabetes risk and A74
– prognosis in type 1 diabetes and A259
– urban *vs* rural – type 1 diabetes risk and 789
Sodium transport – Na^{+}/K^{+} ATPase – C-peptide, effect of A154, A201
– – islet B-cell A138
– – loop of Henle – diabetic rat A270
– – nerve – aminoguanidine, effect on 743
– – retina A315
– Na^{+}/Li^{+} counterport – atorvastatin, effect of A288
– – diabetes – type 1 A265
– – – type 2 A23
Sorbitol *[see also* Polyol pathway*]*
– dehydrogenase – inhibitor – nerve, effect on in diabetic rat 1187
Spectral analysis – heart-rate variability A295
Spectrophotometry – microlightguide – human nerve oximetry 737
Squatting test A297
Staged Diabetes Management *[see* Diabetes – care*]* A38
Staphylococcus aureus – methicillin-resistant – diabetic foot A310
Starvation – insulin secretion, effect on 128r
Stat – 6 – hepatocyte – insulin & leptin, activation by A172
Statin *[see* Lipid – lowering agent*]*
Statistical analysis – clustering A6
– twin studies 898c
Stature – short – gestational diabetes association with A259
Steatohepatitis, non-alcoholic *[see also* Hepatic – steatosis*]* A184
Steroid *[see* Glucocorticoid. Mineralocorticoid*]*
Stiff man syndrome A95
Streptozotocin – diabetes induction – poly(ADP-ribose) synthetase role A8
– islet B-cell cytotoxicity – GLUT2, role of A159
– – nicotinamide, effect of 55
Stress – mental – lipolysis, effect on A203
Stroke – mortality – diabetes – type 2 297
Substance P – diabetic nerve, expression in – CB1093, effect of 1308
– microvascular function and – type 1 diabetes A302
Sulodexide *[see* Glycosaminoglycan*]*
Sulphatide – insulin autoreactive T-cell, effect on 1212
– islet B-cell, expression by 1212
Sulphonylurea – ACE inhibitor interaction A68
– extrapancreatic effects 903r
– glibenclamide – active metabolites A243
– glimepiride – myocardial infarction, effect on A282
– – myocardial perfusion, effect on A280
– herbicides 903r
– history 903r
– insulin secretion, effect on – down-regulation A130
– islet B-cell selectivity 903r
– – gliclazide 845
– latent autoimmune diabetes in adult, role in A209
– metformin with – mortality in diabetes and A3
– myocardial infarct size, effect on – diabetic rabbit A282
– myocardial perfusion, effect on A280
– pharmacokinetics – ageing, effect of A244
– receptor 903r, A130
– – 1 – localisation in rat pancreas 1204
– – binding A65
– – cardiac *vs* islet B-cell 903r
– – gliclazide, effect of – cardiac *vs* islet B-cell 845
– – isoforms – mRNA-injected *Xenopus* oocyte 845
– – – sulphonylurea tissue selectivity and 845
– – polymorphism – type 2 diabetes 617
– structure – selectivity and 903r
– therapy – thiazolidinedione with A227, A229
Superantigen – type 1 diabetes 413
Superoxide *[see* Oxygen – free radicals*]*
Surgery – diabetes and – cardiac surgery A282
Synapsin – insulin secretion, role in A136, A35
Syndrome X – cardiac A76, A183, A188
– metabolic *[see* Insulin – resistance – syndrome*]* A76

T

T cell *[see* Lymphocyte – T*]*
Tacrolimus – diabetogenicity A98
Tanacan *[see* Antioxidant – Tanacan*]*
Taste cell – G-protein – α-gustducin A129

Taurine – diabetic retinopathy prevention in rat A315
Telemedicine *[see* Information technology]
Temperature – insulin storage, importance in 257c
– low *[see* Hypothermia*]*
Teratogenesis in diabetic pregnancy A22
– oxygen free radical scavengers, effect of A247
Tetraplegia – skeletal muscle uncoupling protein expression 826
Tetraploidy – diabetic nephropathy and 118c
Thapsigargin – platelet Ca^{2+} signalling, effect on 167
Thiazide – K^{+}_{ATP} channel, effect on A130
Thiazolidinedione *[see also* Hypoglycaemic agent – isoxazolidinedione*]* A180-A182
– adipocyte, effect on – differentiation 527
– cytokine-suppressed PPARγ expression, effect on 702
– darglitazone – *fa/fa* rat, effect on A181
– – triglyceride kinetics, effect on A206
– mechanism of action 1033r
– naphthiazo – immortalised adipocyte, effect on 527
– PAT5A A229
– pioglitazone A227, A228
– – immortalised adipocyte, effect on 527
– – insulin signalling, effect on A182
– PPARγ-specific – KRP-297 A15
– renoprotective effect in streptozotocin-diabetic rat A276
– rosiglitazone A181, A227-A231
– – glycaemic control, effect on A4
– – hepatotoxicity A3
– – islet, effect on A150
– – left ventricular function, effect on A68
– troglitazone A226, A228, A229
– – adipocyte insulin sensitivity, effect on 949
– – inflammatory markers, effect on 1433
– – islet B-cell, effect on – protein expression A156
– – NOD mouse islet, effect on A94
– – T-cell, effect on – NOD mouse A103
– – therapy – diabetes – type 2 1433
– – – repaglinide, with A241
– – type 2 diabetes families, effect in A44
– uncoupling protein 1, effect on A206
Thioctic acid *[see* Antioxidant – α-lipoic acid*]*
Thirst – impaired – HONK survivors 534
Thrifty gene – hypothesis 383c, 384c
– PPARγ 1033r
Thrombomodulin – endothelial dysfunction marker – diabetic nephropathy 222
Thymus – insulin-related peptides – BB rat A29
– medulla – structure – NOD mouse A29
Thyroid – autoimmunity – type 1 diabetes, in A262
– metabolic aspects A203
Tilt test A23, A297
Transcript peptide – cocaine and amphetamine-regulated A194
Transcription factor – ATF-2 – insulin expression, role in A124
– BETA2/NEUROD1 – polymorphism – type 2 diabetes 480
– Egr-1 – glucose-stimulated insulin-secreting cell 195
– insulin promoter factor 1 A77
– insulin-secreting cell – glycation, effect of 1417
– ISL-1 – mutation – diabetes – type 2 A119
– NF-κB – α-lipoic acid, effect of 222
– – diabetic nephropathy, in 222, A273
– – islet B-cell, role in A13, A14
– PAX4 – polymorphism – type 2 diabetes 480
– PDX-1 (pancreatic and duodenal homeobox gene 1)
– – insulin-secreting cell 856, 1417, A24, A25
– zinc-finger – glucose-stimulated 195
Transfection – human myoblast – GLUT-4 – insulin resistance, effect on A16
Transglutaminase – autoantibodies – type 1 diabetes 1195, 1441c
Transplantation – immune tolerance 1379c
– immunosuppression – mycophenolate mofetil A105
– – tacrolimus A98
– islet *[see also* Islet – storage*]* A31-A33, A216, A217, islet EASD News Section 8/99 33w
– – animal model – HU-PBL-SCID mouse A104
– – antigen expression A30
– – early failure mechanism – NOD mouse A104
– – hyperglycaemia, effect of A158
– – insulin signalling in diabetic rat heart, effect on A67
– – microencapsulation – macrophage response A105
– – tolerance induction A105
– – xenorecognition 330
– pancreas A31, A32, A217, A218, EASD News Section 8/99 33w
– – left ventricular function, effect on A282
– – mismatched – tolerance to prior renal graft 1379c
– renal – glucose homeostasis following A154, A176
– xenograft – porcine in human recipient A216, A217
Triacylglycerol – glucose effectiveness, effect on A162
Tricarboxylic acid cycle *[see* Krebs cycle*]*
Triglyceride – transfer protein – diabetic rat intestine 944
Trigonella foenum graecum – 4-hydroxyisoleucine A129
trkA – nerve growth factor receptor 1308
Troglitazone *[see* Thiazolidinedione – troglitazone*]*
Tumour necrosis factor – α – diabetes – type 2 A83
– – glomerular – diabetic rat 878
– – insulin resistance, role in A175
– – insulin secretion, effect on A56
– – insulin-secreting cell, effect on A143
– – metabolic effects 1367r
– – PPARγ expression, effect on 702
– – promoter polymorphism A20, A117
– receptor – soluble – diabetic nephropathy, incipient A273
Twin study – diabetes – type 1 – cytokine patterns 1080
– – type 1 – telomere length A91
– – type 2 125r, 139, 146
– – – low birth weight 898c
– glucose tolerance A113
– statistical analysis 898c
Tyrosine kinase – Bsk/lyk – phaeochromocytoma cell, effect on A151
Tyrosine phosphatase IA-2 – insulin-secreting cell, expression in A8
– type 1 diabetes and 3r

U

UGPD Study 1r
UKPDS (United Kingdom Prospective Diabetes Study) 1r
– diabetic nephropathy – ethnicity A277
– diabetic retinopathy in 1107
– GAD antibody and progression to insulin requirement 499 r
– hepatic nuclear factor alpha polymorphism 120c
– HLA and islet autoimmunity in type 2 diabetes 608
– islet-cell antibodies – glycaemic control and A81
– lipids A18
– macrovascular disease – insulin resistance and A187
Ulcer – skin *[see* Foot; Wound*]*
Ultrasound – abdominal obesity, assessment of A208
Uncoupling protein – 1 – polymorphism – obesity and A21
– 2 – expression – thiazolidinedione effect – adipocyte 527

Uncoupling protein
– – polymorphism – obesity and 688, 1413
– 3 – polymorphism – abdominal obesity A117, A119
– – skeletal muscle, expression in – obesity 302
– expression A206
– insertion polymorphism 1413
– skeletal muscle, in – physical activity, effect of 826
Urine – infection – asymptomatic bacteriuria in type 2 diabetes A220
– markers of endothelial function – type 1 diabetes A23

V

Vaccination – immune response – diabetes A97
Vascular *[see also* Adhesion, Artery, Athero. ., Capillary, Endothelial, Platelet*]*
– disease – peripheral – ankle:brachial index A319
– – peripheral – rotational atherectomy A49
– hypertrophy – diabetes – AGE inhibitors, protection by 472
– inflammation – type 2 diabetes A329
– reactivity – aminoimidazole carboxamide riboside, effect of A324
– – diabetes A75, A325, A326
– – – duration-dependent 204
– – – type 1 A323, A324
– – insulin-induced – endothelium-independent 831
– – insulin-mediated 493c, 494c, 1376c
– – offspring of diabetic pregnancy, in – rat 76
– – retinal A315, A316
Vasoactive intestinal polypeptide (VIP) – insulin secretion, effect on A147
Vasodilation – postprandial – hyperinsulinaemia and A188
Vasopressin – secretion – HONK survivors, in 534
Virus – Coxsackie B – islet B-cell, effect on A157
– encephalomyocarditis – diabetes induction in RAG-2 knockout mouse A103
– entero – islet-cell related antibodies following A99
– hepatitis – C – diabetes and iron stores A221
– herpes simplex I – islet gene transfer by A149
– human immunodeficiency – treatment – indinavir A179
– – – protease inhibitor A221
– innate defence system – type 1 diabetes, activated in A62
– retro – human endogenous – HERV-K10 – type 1 diabetes 413
– – – IDDM1,222 – type 1 diabetes 413
– – porcine A216
Visual function – diabetes A315
Vitamin – B_{12} – serum – metformin, effect of A224
– C – adipocyte insulin sensitivity, effect on 949
– – endothelial function, effect on – insulin resistance A328
– – intra-arterial injection – insulin resistance, in A189
– – oxidative stress, effect on in type 2 diabetes A281
– – plasma – glucose tolerance and A5
– D – 1,25 dihydroxy – insulin sensitivity, effect on A190
– – analogue – 1α,25$(OH)_2$lumisterol$_3$ – islet B-cell, effect on A127
– – – CB1093 – neuroprotective in diabetic rat 1308
– – binding protein – polymorphism – type 1 diabetes A91
– – infancy, supplementation in – type 1 diabetes risk after 51
– – receptor – polymorphism – type 2 diabetes A121
– E – adipocyte insulin sensitivity, effect on 949
– – DNA oxidation, effect on in diabetes A215
– – fenofibrate with – lipoprotein oxidability, effect on A289
– – insulin resistance, effect on – rat A214
– – lipoprotein peroxidability, effect on – type 1 diabetes A46
– – oxidative stress, effect on in type 2 diabetes A281
– – teratogenesis in diabetic pregnancy, effect on A22
Von Willebrand factor *[see* Haemostasis*]*

W

Wagner classification of foot ulcers A307
Wolframin 627
Wound dressings & grafts A307
– hyaluronic acid ester A29
– skin culture preparation A28

X

Xenograft *[see* Transplantation*]*
Xenopus oocyte – Kir6.2 and SUR1/SUR2 co-expressing – gliclazide effect 845

Y

Yeast – glucose stimulation – early response gene induction 195